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ABSTRACT 
Mycobacterium tuberculosis remains as a global burden today with an estimated one-third of the 
global population being infected and at risk of developing active infection. Most studies in the 
immunology and pathogenesis of tuberculosis have revealed the importance of cellular immunity 
in controlling the infection. However, the role of the humoral immune response is poorly 
understood, particularly in the primate models of M. tuberculosis infection. The primary goal of 
this thesis was to understand how B cells and antibody contribute towards containment of M. 
tuberculosis within the cynomolgus macaque model of infection. The thesis starts off by 
characterizing B cells and antibody profiles within the granulomas of M. tuberculosis infected 
cynomolgus macaques. B cells were noted organize themselves into clusters that resemble 
germinal centers found in lymphoid organs or in chronic autoimmune conditions, within the 
granuloma. The effect of B cell depletion on the outcome of M. tuberculosis infection in 
cynomolgus macaques was also performed. The study findings suggest that B cells and antibody 
contribute very little in terms of disease control in the early stages of natural M. tuberculosis 
infection. However, subtle differences such as a slight increase in bacterial burden within 
individual granulomas and altered cytokine correlations within individual granulomas were 
noted. Macrophage behavior in the absence of B cells and antibody was also studied using 
 V 
granuloma tissue derived from the B cell depletion study. No differences were found within the 
macrophages in the absence of B cells at least at the acute stage of infection. The experiments 
detailed in this thesis suggest that the humoral response is not crucial towards M. tuberculosis 
control in the early stages of natural infection. However, the findings in this thesis suggest that B 
cells and antibody may play a role in long term chronic control of tuberculosis infection.       
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2.0  AN INTRODUCTION TO TUBERCULOSIS 
2.1 A BRIEF HISTORY OF A SUCCESSFUL PATHOGEN 
Tuberculosis (TB) occupies a unique position in human history as one of the most successful 
diseases that has plagued humanity until today. Mycobacterium tuberculosis, the primary 
causative agent of TB in humans, is thought to have been infecting early humans migrating out 
of East Africa approximately 3 million years ago and has continued to persist throughout 
history
1
. Characteristic bone deformations found in mummified remains from Egypt around 3000 
BC showed very clear signs of Potts disease (spinal form of TB), suggesting that TB itself has 
been present since early human history
2
. The disease itself has earned many names throughout 
history, phthisis by the ancient Greeks
3, King’s Evil4 during the medieval era and consumption 
closer to the industrialization period of Europe. All these terms share a common theme of 
sufferers being chronically ill, bedridden by bloody coughs and wasting away as if being 
consumed by the disease.  Further findings in paleoarchaeology would undoubtedly reveal 
further evidence that M. tuberculosis has not only persisted but co-evolved alongside humans 
throughout history. 
M. tuberculosis was eventually isolated as the causative agent in 1882 by a German 
physician turned scientist, Robert Koch and proved to be a landmark discovery in microbiology
5
. 
Robert Koch was hailed as the forefather of microbiology due to his scientific principles in 
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identifying infectious agents known as the Koch’s postulates, that were instrumental in 
identifying many other pathogens such as Vibrio cholera
6. With regards to TB, Robert Koch’s 
work also provided the means to diagnose patients with the disease such as the tuberculin skin 
test which is still routinely used today
7
.  
Despite the isolation of M. tuberculosis, adequate treatment and vaccination modalities 
were not discovered until the early 20
th
 century. Until then, various treatments for TB were 
present from the ingestion of laudanum
8
 to admitting patients in sanatoriums in the belief that 
fresh air, graduated labor, exercise and diet would ameliorate the disease
9. It wasn’t until 1908 
that Albert Calmette and Camille Guérin developed an attenuated strain of Mycobacterium bovis, 
a cousin of M. tuberculosis that infects primarily cattle and badgers, to serve as a vaccine. This 
was accomplished by passaging the virulent M. bovis on an alkaline glycerin-ox bile-potato 
media over 200 times until the strain becomes sufficiently attenuated for human use
10, 11
.  This 
vaccine, termed the bacille Calmette-Guérin (BCG), is still in use by many countries worldwide 
and has lowered the incidence of more sever extra-pulmonary dissemination of disease such as 
tuberculous meningitis especially in children
12, 13
.  
With the advent of antibiotics, particularly streptomycin in 1943
14, 15
, and then the 
introduction of the anti-tuberculosis drug cocktail starting from the 1960s
16
, global attention 
towards TB begun to wane as the disease was seemingly brought under control. However, TB 
has made a dramatic return in recent decades in part due to the human immunodeficiency virus 
(HIV) pandemic ravaging across the world
17
. To compound matters further, antibiotic resistant 
strains of M. tuberculosis are also on the rise due to a combination of inadequate drug treatment 
regimens, socio-economic collapse and poor monitoring programs in various involved 
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countries
18, 19
. Given how TB has persisted alongside humans throughout history, it is not 
surprising that eradication of such a tenacious pathogen remains difficult.  
2.2 MICROBIOLOGY AND EPIDEMIOLOGY OF M. TUBERCULOSIS 
The causative agent of TB in humans, M. tuberculosis, is part of a group of phyllogenetically 
related group of bacteria termed the M. tuberculosis complex (MTBC)
20
. Aside from M. 
tuberculosis, Mycobacterium africanum is another member of the MTBC which has adapted as a 
human pathogen
21
. There are also members of the MTBC that has adapted to using both wild and 
domesticated animals as hosts such as M. bovis (cattle and badgers), Mycobacterium caprae 
(sheep and goat), Mycobacterium microtii (voles) and Mycobacterium pinnipedii (seals and sea 
lions)
22
. The animal-adapted MTBC members are capable of causing disease in humans, as 
demonstrated by M. bovis infections in children from consuming tainted raw milk
23
, but has 
limited human to human transmission capabilities
24
. 
The human adapted MTBC members, M. tuberculosis and M. africanum can be further 
differentiated into distinct genetic lineages
25
. The geographical distribution of these lineages of 
human adapted MTBC correlate very closely with certain human populations, suggesting that 
human adapted MTBC lineages have adapted to utilize certain human genotypes as hosts
25
. 
Africa is unique as it harbors the highest diversity in human adapted MTBC lineages. This 
observation suggests that human adapted members of MTBC originated in Africa and have 
coevolved along with their respective human population after the migration out of the continent 
approximately 70000 years ago
26
 (Fig. 1.). The resultant spread of the different lineages of 
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human adapted MTBC members in modern times can be attributed to trade, exploration and 
conquest throughout recorded history
26
.  
 
Figure 1. Phylogenetic tree and geographic distribution of the various global lineages of Mycobacterium 
tuberculosis complex. Image adapted, with permission, from Gagneux et al.
25
 Copyright (2006) National Academy 
of Sciences, USA.   
 
TB is very much a disease of the poor and correlates very closely with poverty levels 
within any given population
27
. During the period of the Industrial Revolution of Europe from the 
late 18
th
 century to the early 20
th
 century, mortality rates due to TB skyrocketed from the 
rampant poverty, malnutrition and overcrowding
28
. Today, the same socioeconomic factors 
influence the distribution of TB globally. Current estimates suggest that roughly one third of the 
human population is infected with M. tuberculosis, with a smaller fraction (around 10 percent) 
presenting with clinical signs of active disease
29
. Global active TB incident cases currently 
stands at 8.7 million with 1.5 million deaths per year. Countries with the highest incidence and 
mortality rates in 2011 are in sub-Saharan Africa, South East Asia and North Korea. Aside from 
poverty, some of these areas also contain the highest HIV prevalence rate which exacerbates the 
already heavy TB burden present
29
 (Fig. 2).     
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Figure 2. World map depicting the incidence rates of tuberculosis. Figure was reused, with permission, from the 
World Health Organization (WHO) Global Tuberculosis Report 2012.
29
  
2.3 HOST IMMUNOLOGIC RESPONSES TO M. TUBERCULOSIS  
M. tuberculosis is primarily spread via aerosol droplets generated from an actively infected 
individual. The primary site of infection is typically the respiratory tract, more specifically the 
alveolar macrophages or alveolar dendritic cells upon phagocytosis of bacilli containing droplets. 
Deposition of bacteria within the lung alveolar spaces are less likely to be cleared compared to 
deposition within the airway due to the tendency of resident APCs to induce tolerance
30, 31
. 
Hence, M. tuberculosis has a better chance at establishing a productive infection if the bacilli-
laden aerosol is deposited within the lung parenchyma than the airway as immune cells of the 
airway mucosa tends to be more microbicidal
30, 31
. Upon detection of the bacilli, pathogen 
recognition receptors are activated resulting in the release of pro-inflammatory cytokines and 
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chemokines that recruit other monocytes and dendritic cells to the site of infection
32
. This wave 
of cellular recruitment is thought to be an attempt to contain the infection
33, 34
 while allowing for 
the infected dendritic cells to migrate to the draining lymph nodes to begin the priming of the 
adaptive immune system to recognize M. tuberculosis antigens
35, 36
. Primed lymphocytes, both T 
and B cells then migrate to the lungs between 2 to 6 weeks post infection leading to the 
formation of a granuloma
37, 38
. Successful containment of the bacilli within granuloma can lead 
to either bacterial clearance or latent infection whereby the infection remains clinically dormant, 
sometimes for the lifetime of the host. However, failure to contain the bacilli results bacterial 
dissemination, leading to granulomas forming throughout the lungs and other organs. More 
severe forms of the disease result in lung cavitation as the granulomas begin to erode away 
normal tissue or even miliary disease, where systemic bacterial dissemination causes granulomas 
to form all over the body
39
.  
A functional granuloma is thus essential in containing M. tuberculosis and requires the 
cooperation of a myriad of cells ranging from macrophages, neutrophils, fibrocytes and 
lymphocytes
40, 41
. In primate TB, there is a huge variation in the pathology of the granuloma 
ranging from a spectrum of solid cellular, caseus necrotic, fibrotic or mineralized
42, 43
. 
Furthermore, the outcome of each individual granuloma is unique and independent of each other 
even within granulomas from the same individual
44
. This suggests that the local interplay 
between host and pathogen is crucial in dictating the outcome of each granuloma.   
2.3.1 Roles of the macrophages.  
The primary function of alveolar macrophages is to keep the airway clear by phagocytosis. They 
are thus the first to encounter M. tuberculosis upon ingestion of the bacilli laden aerosols
45
. Entry 
 7 
into the macrophage is typically mediated by the binding of mannose receptors, notably DC-
SIGN
46, 47
, complement receptors such (CR) as CR1
48
, 3
49
 and 4
48
 or via Fc receptor engagement 
with antibody, specifically of the FcγR family50. DC-SIGN engagement typically promotes an 
anti-inflammatory phenotype in macrophages which is beneficial to the invading bacilli
51
. 
Engagement of activating FcγR promotes bacterial killing and the secretion of pro-inflammatory 
cytokines by the macrophage
52
. The mode of entry into the macrophages is thus crucial as it can 
modulate macrophage activation and affect the bacterial clearance efficacy downstream. 
Within the cell, M. tuberculosis is detected by several groups of pathogen recognition 
receptors such as members of the Toll-like receptor (TLR) family and NOD-like receptors
53-56
. 
TLR2 has been shown to interact with a 19kDa lipoprotein
57
 while TLR4 recognizes cell 
associated factors specific for M. tuberculosis
58, 59
. TLR activation typically leads to the secretion 
of pro-inflammatory cytokines such as IL1β60, 61 and tumor necrosis factor (TNF) and 
chemokines leading to the recruitment of more monocytes and macrophages to the site of 
infection to begin granuloma formation
35, 36, 62
. TLR activation can also be subverted by M. 
tuberculosis as a means to mediate immune evasion by down-regulating IFNγ induced killing57 
or reduce apoptosis within infected macrophages
63
.  
M. tuberculosis may secrete virulence factors that actively result in macrophage 
recruitment initially in order to increase the number of infected cells
33-35
. This is done by 
inducing the infected cells to undergo necrosis by directly damaging the cell membrane and 
blocking the membrane repair mechanism
34
. As necrotic cells induce active inflammation, more 
phagocytotic cells are recruited leading to more potential targets for M. tuberculosis infection
64
.  
Within the granuloma in humans and non-human primates, infected macrophages are 
typically confined to the center while being surrounded by a layer of epitheliod macrophages, in 
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an attempt to wall off the bacteria and prevent dissemination
41-43
. The center of the granuloma 
thus becomes necrotic and highly hypoxic in an attempt to impair mycobacterial growth
65
.    
M. tuberculosis has a variety of ways to evade the immune response and survive within 
the macrophage. Secreted virulence factors such as the 19kDa lipoprotein are capable of down 
regulating antigen presentation via MHC class II within macrophages and dendritic cells
66
 and 
downregulate IFNγ dependent killing mechanisms57, 67. Mycobacterial cell wall components are 
also capable of arresting phagosome maturation and fusion with the lysosomal compartment into 
the phagolysosome
68
, allowing for internalized bacilli to survive within the phagosome of 
macrophages
69
.     
Macrophages thus need to be primed for effective bacterial killing. Interferon γ (IFNγ) 
and TNF secreted by activated lymphocytes, typically CD4
+
 Th1 T-cells are capable of activating 
macrophages into a classically activated phenotype (M1)
70
 to kill any ingested bacilli
71
. These 
M1 activated macrophages tend to produce more reactive oxygen and nitrogen species
72
 and are 
capable of further acidifying the phagolysomal compartment where internalized M. tuberculosis 
are present
73
. However, macrophage activation needs to be confined and balanced within the 
granuloma as extensive tissue damage can occur otherwise, leading to extensive inflammation, 
impairment of bacterial containment and bacterial dissemination
41, 74
.  
Macrophages can also take on an alternatively activated (M2) phenotype in response to IL4, IL5, 
IL10 and IL13
70, 75
. M2 macrophages are more closely associated with down regulating immune 
responses by secreting anti-inflammatory cytokines such as IL10 and transforming growth factor 
β (TGFβ)76. M2 macrophages are also capable of promoting fibrosis to begin the resolution 
phase of the inflammatory process
70, 77-79
. Within the granuloma, M2 macrophages are crucial as 
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they may limit the amount of tissue pathology that results from excessive pro-inflammatory 
microbicidal responses.  
2.3.2 T-cells. 
T-cells are an essential component in any immune response against pathogens. In the case of 
tuberculosis, T-cells have been found to be an indispensable component in controlling the 
infection. This is most evident in αβ T-cell receptor mutant mice where these mice succumb very 
quickly to M. tuberculosis infection much earlier compared to wild type counterparts and present 
with greater pathology and higher bacterial burden
80, 81
. Further knockout mice studies have 
since revealed the relative importance of various subsets of T-cells in shaping the immune 
response to M. tuberculosis over the course of infection. From the mouse studies, CD4 T-cells 
were noted as key players in organizing the immune response within the granuloma
82, 83
 via 
cytokine secretion, in particular IFNγ84 and TNF85. CD8 T-cells were primarily noted for 
cytotoxic functions such as mediating apoptosis of heavily infected macrophages or dendritic 
cells via granzyme B, perforin
86-89
 and in the case of humans, granulysin production
90
.  
In humans, the importance of T-cells in the control of M. tuberculosis is evident from 
several clinical observations. HIV-1 infected patients have an increased risk of M. tuberculosis 
infection, disease, and increased risk of reactivation from latent infection, highlighting the 
importance of CD4 T-cells in controlling M. tuberculosis as HIV primarily targets CD4 T-cells 
and macrophages
91-93
. Another observation is that patients with recurring mycobacterial infection 
tend to have genetic lesions within certain T-cell cytokine signaling pathways particularly within 
the IL12, IL23 and IFNγ axis94, 95. These genetic studies highlight the importance of cytokine 
signaling in orchestrating an effective response towards controlling intracellular infection by T-
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cell dependent pathways. Furthermore, patients taking pharmacological inhibitors of TNF are at 
high risk of reactivation of latent tuberculosis, which again reinforces the importance of adequate 
cytokine signaling in controlling M. tuberculosis infection
96, 97
.        
2.3.3 Cytokines orchestrate cellular interactions within the granuloma. 
Successful containment of M. tuberculosis depends upon adequate cellular signaling within the 
granuloma for proper bacterial clearance and to confine damaging pro-inflammatory reactions to 
reduce tissue damage
41
. The complex interplay of cytokine signaling continues to be unraveled 
with various cytokines taking up roles in mediating pro- or anti-inflammatory responses or 
specific cellular activation in the case of T-cells and macrophages
40
. Thus, granulomas are 
incredibly complex and dynamic immunologic structures with very unique microenvironments 
for cellular behavior due to the diversity of cytokine interactions present.  
Cytokine signaling is thought to set the context of subsequent immunologic responses 
upon detection of specific pathogens by tissue resident macrophages or dendritic cells. In the 
case of tuberculosis, detection of the pathogen via the TLR2, TLR4 and TLR9 
54
is thought to 
promote IFNγ and IL12 production to prime CD4 T-cells towards the TH1 lineage for further 
release of IFNγ and TNF48. These cytokines are essential as they synergize to further activate 
macrophages for anti-microbial functions through the release of nitric oxide synthase (iNOS) and 
reactive radical species
98, 99. IFNγ also serves to enhance the antigen presentation capabilities of 
macrophages towards intracellular antigens, thereby promoting further immune activation 
against M. tuberculosis
73
. Furthermore, CD4 T-cells are helper cells and would thus signal to 
other cell types such as CD8 T-cells to mount the appropriate response to the specific pathogen, 
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in the case of tuberculosis, more IFNγ and TNF production for enhanced macrophage activated 
killing
71, 75
 or direct cytotoxic capacity
100
. 
TNF and other members of the TNF superfamily are also indispensable in the 
establishment of the granuloma as TNF deficient mice are highly susceptible to M. tuberculosis 
infection
85, 101
. In humans, reactivation of tuberculosis is a major risk for patients under anti-TNF 
therapies, highlighting the crucial role TNF occupies within the immune response to M. 
tuberculosis
96, 102
. Aside from its role in activating macrophages along with IFNγ, TNF is crucial 
as a signaling molecule to initiate further immune activation via cytokine and chemokine 
signaling responsible for cellular recruitment.  In TNF deficient mice, granuloma formation was 
delayed due to less monocyte recruitment to the site of infection and reduced chemokine 
secretion by infected macrophages
103, 104
. Furthermore, TNF signaling is crucial for the 
maintenance of granuloma function, particularly the chemokine gradients necessary to 
orchestrate macrophage and lymphocyte localization and function within the granuloma
101
. 
However, the originally assumed role of TNF in granuloma formation and maintenance 
identified in the mouse was not observed in non-human primates treated with anti-TNF 
antibody
105
. Although anti-TNF antibody resulted in exacerbated acute infection and reactivation 
of latent infection in macaques, granuloma structures formed and remained intact. However, 
these granulomas were not apparently capable of controlling infection, and dissemination was 
rampant. Normal granuloma structure was also observed in human patients treated with anti-TNF 
for inflammatory diseases that subsequently developed reactivation tuberculosis.  
Other inflammatory cytokines involved in M. tuberculosis infection include IL1 family 
members, IL6 and IL17. Macrophages are known to produce IL1 and IL6 upon interaction with 
M. tuberculosis
106, 107
. IL1 members particularly IL1β and IL18 are essential in activating 
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inflammatory responses via inflammasome assembly and promote IFNγ production by T-cells108-
110
. IL6 in particular has prominent roles in activating T-cell, particularly in the development of 
the TH17 T-cell subset and B cell responses. TH17 T-cells secrete IL17, a potent cytokine that 
helps to recruit neutrophils to the site of immune activation
111
.  
Macrophages also need to be activated in a controlled manner to limit tissue pathology as 
uncontrolled inflammatory processes can result in bystander tissue damage. IL10 is an example 
of an immune suppressive cytokine that down-regulates immune cell activation
112
. CD4 T-
regulatory cells, formed during T-cell activation via antigen recognition, and macrophages are 
capable of producing IL10
113, 114
. However, adequate control of IL10 production is crucial as the 
suppressive activities of this cytokine can also hinder proper pathogen control
112, 115
. 
2.4 TREATMENT MODALITIES FOR TUBERCULOSIS 
Antibiotics are available for the treating tuberculosis but suffer from several issues. The most 
pressing is that adequate treatment requires the administration of several antibiotics over a long 
period of time. The standard short course chemotherapy consists of 4 first-line drugs, isoniazid 
(INH), rifampicin (RIF), ethambutol (ETH) and pyrazinamide (PZA) taken in combination daily 
over a period of 6 months
116
. The long treatment period was deemed necessary due to the 
inherent slow growing nature of M. tuberculosis. However, patient compliance in adhering to the 
drug regiment over such a long period proved to be difficult, which frequently results in the 
emergence of drug resistant tuberculosis
117, 118
.  
Second-line antibiotics are available but are typically reserved for cases of multi-drug 
resistant M. tuberculosis strains (MDR-TB). MDR-TB strains are defined as M. tuberculosis 
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strains resistant to two or more first line drugs, usually INH and RIF
118
. These strains require 
even longer treatment periods that can exceed 2 years with varying efficacy
119, 120
. The second-
line drugs include aminoglycosides such as kanamycin, fluoroquinolones including levofloxacin, 
thioamides and various polypeptide based drugs such as capreomycin
121
. These drugs are more 
toxic, can be more difficult to administer and are not widely available in low income countries, 
making them prohibitively expensive
122, 123
.  
Multidrug resistant strains of M. tuberculosis are of great concern especially with the 
emergence of extremely drug resistant varieties (XDR-TB) which can be impervious to even the 
second-line drugs. In light of such highly resistant strains, finding new drug targets and 
developing new antibiotics is crucial to keep treatment options open
124
.  
2.5 ANIMAL MODELS FOR TUBERCULOSIS  
Animal models of human diseases are essential in providing invaluable insight into host-
pathogen interactions essential for establishing new treatment modalities, vaccines and drug 
research. In the case of tuberculosis, many animal models are available for research purposes, 
each with its own set of advantages and shortcomings. However, data from all the animal models 
have provided invaluable data into defining host-pathogen interactions of tuberculosis with 
humans.  
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2.5.1 Murine model of tuberculosis. 
The mouse model (Mus musculus) is currently the most widely used model of study in 
tuberculosis research. This animal model has many advantages. The mouse is a versatile model 
due to the ease of genetic manipulation which allows for the identification of host genetic factors 
via gene knockouts or overexpression systems. Through use of knock-out mice models, many 
genetic determinants such as IFNγ, TNF and various cell populations crucial to the control of 
tuberculosis were identified
84, 85, 125, 126
. Furthermore, research reagents are very widely available 
due to the widespread use of the mouse model in other fields of study. 
The mouse is also cheap as they can be housed easily, thus reducing the overall research 
costs. This model is easily infected with a variety of M. tuberculosis strains via intravenous or 
aerosol routes of infection which allows for vaccine and drug studies to be conducted with 
minimal complications
127
. Thus, the mouse model is the most widely used disease model in M. 
tuberculosis research.  
Despite these advantages, the murine model does present with certain shortcomings in 
terms of disease progression and pathology. M. tuberculosis infection is progressive in all mouse 
strains and mice do not develop latent infection as in the case of human tuberculosis
128, 129
. 
Although several manipulations using drugs to mimic latency are available, this still limits the 
understanding of factors involved in controlling the disease at the latent stage in humans
125
.  
In addition, granuloma formation in mice does occur but lacks the highly organized 
cellular structures seen in human granulomas. Caseus necrosis is absent unless several genetic 
factors crucial to immune function are ablated leading to abnormally high bacterial burden in the 
lung. Even then, the disease pathology does not resemble actual human caseous granuloma 
pathology. Furthermore, murine M. tuberculosis infection typically results in poorly formed 
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cellular ‘granulomas’ and eventually progresses to fatal cellular infiltration of the lungs by 
macrophages, neutrophils and lymphocytes
130
.  
It should thus be noted that the mouse model can be useful if the research question is 
properly phrased. The eventual goal is to translate the findings in the murine model for use in 
human disease treatment.  
2.5.2 Non-human primate model of tuberculosis. 
Research of tuberculosis in non-human primates are generally performed on macaques, 
particularly using rhesus (Macaca mulatta)
131
 and cynomolgus (Macaca fasicularis) macaques
42
. 
Characterization of infection within these animals revealed that disease aetiology and pathology 
very closely mimic the spectrum of infection in human tuberculosis, including both active and 
latent disease. Although tuberculosis has been characterized more in cynomolgus macaques, 
rhesus macaques are still used due to the extensive work done in related infectious disease fields 
of simian immunodeficiency virus (SIV) as a surrogate model of HIV.  
Infections in monkey models are done via bronchoscope instillation of bacteria (generally 
20 to 200 CFU) or aerosol route. Infected animals can be followed up using a range of clinical 
indicators for inflammation and infection such as erythrocyte sedimentation rates (ESR), C-
reactive protein, chest X-ray to detect for pulmonary infiltration, or culture positivity of gastric 
aspirate or bronchoalveolar lavage fluid (BAL). All infected animals also can be confirmed for 
infection using the tuberculin skin test 4 to 8 weeks posts infection
42, 43
. 
Pathology in the non-human primate model recapitulates the entire spectrum of 
granulomas observed in human tuberculosis. Granulomas from non-human primates are similar, 
even indistinguishable from human granulomas in terms of gross appearance and microscopic 
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presentation, including the broad range of granuloma types from caseus necrotic, fibrotic, 
mineralized or solid cellular granulomas. In terms of disease presentation, tuberculosis in non-
human primates also progresses in a similar manner to humans with the classical Ghon complex 
presentation (pulmonary granuloma with associated lymph node involvement), lung cavitation, 
and even atypical presentations such as Pott’s disease and tuberculous meningitis to reflect 
disseminated disease
42, 43
. These marked similarities thus allow for findings in research to be 
easily applied for human use. The availability of real-time imaging technology such as PET/CT 
in tracking disease progression also facilitates the use of the monkey model in the development 
of vaccines and drugs against tuberculosis
132-134
. 
The most important hallmark of the non-human primate model is latent infection. An 
animal model for latent tuberculosis infection is invaluable in dissecting the mechanisms that 
induce latent infection, and the associated risk factors that govern disease reactivation
135-137
. This 
is crucial as the majority of humans infected with M. tuberculosis are latently infected. 
Furthermore, the non-human primate model may be helpful in dissecting the problem of HIV-TB 
co-infection where tuberculosis remains a major killer among people with HIV
138, 139
. 
However, non-human primates are far more costly to maintain for research compared to 
small animals such as mice. The economic factor alone to maintain monkeys in BSL3 conditions 
is staggering, thus prohibiting widespread use. Monkeys are also highly outbred unlike the 
laboratory mouse which necessitates the use of more animals in research studies, adding to the 
cost. However, the outbred nature of the animals themselves allow for the research data to be 
more easily applied to humans as humans are an outbred population and could explain the 
variable outcome of disease presentation in both monkey and human groups.  
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Another limitation is the availability of research reagents tailored for monkey use. 
However, many human specific reagents can cross react with non-human primate samples and 
the increasing use of macaques in other infectious disease fields may help spur further reagent 
development specifically for non-human primate research use.  
2.5.3 Other mammalian models of tuberculosis. 
The New Zealand White rabbit is currently the most commonly used rabbit species in 
tuberculosis research. Like mice and non-human primates, rabbits are also susceptible to M. 
tuberculosis infection via various routes depending on the model being studied
65, 140-144
, although 
they are much more susceptible to M. bovis
144, 145
. Rabbits are also used in tuberculosis research 
to as models for tuberculosis meningitis when the bacilli gains access to the central nervous 
system (CNS)
146, 147
. CNS complications from tuberculosis in humans are the most complicated 
to treat, with a mortality rate as high as 50 percent
148
. The tuberculous meningitis rabbit model 
has provided insight into treatment modalities to reduce brain damage by including 
immunomodulatory drugs in addition to standard anti-tuberculous drugs
146, 148
.   
The major drawback for the rabbit model is the availability of reagents for research which 
limits the scope and depth of questions being addressed. Rabbits are also more costly to handle 
compared to mice which limits the number of people willing to invest in the model.  
Other common tuberculosis models include the guinea pig
149
, cattle
150, 151
, and 
zebrafish
152
. Each has strengths and weaknesses, but all have been used to further our 
understanding of the host-pathogen relationships in mycobacterial infections. 
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3.0  AN INTRODUCTION TO B CELLS: 
3.1 THE HUMORAL IMMUNE SYSTEM  
The humoral immune system is a component of the adaptive immunity that is responsible for 
protecting the extracellular spaces of the host from pathogens. B cells are the main players of the 
humoral immune system as they differentiate into plasma cells upon activation with appropriate 
cognate antigen and associated signals to produce antibodies
153
. Antibodies are secreted 
immunoglobulins and are the primary proteins that mediate the interactions of the humoral 
response with the rest of the immune system. Antibodies function by binding to their antigenic 
targets upon recognition and mediate clearance via neutralization
154, 155
, enhancing 
opsonization
156
 or complement activation
157
. Antibodies, when bound to cognate antigen, form 
immune complexes which are capable of mediating cellular signaling to cells bearing the 
appropriate Fc receptors
158
. Thus, Fc receptors provide a mechanism by which components of 
the humoral immune system such as antibody-antigen immune complexes can modulate the 
immune response
159
.   
B cell activation is a key process in the initiation of the humoral response and is tightly 
regulated. As mentioned above, B cell activation requires both cognate antigen recognition by 
the B cell receptor complex (BCR) and outside help in the form of helper CD4
+
 T-cell 
signaling
160
 or TLR activation via pathogenic components such as CpG or LPS
161
. The BCR 
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itself is a membrane bound immunoglobulin, similar to antibodies, and is highly variable in 
sequence, allowing for diverse antigen recognition capabilities
162
. Upon activation, B cells 
undergo a complex set of differentiation and specialization processes to form plasma cells whose 
sole function is to secrete huge quantities of antibodies
153
. A subset of activated B cells also 
differentiates into memory B cells to confer long term protection to the host against previously 
encountered antigen
163
.  
B cells are also recognized to provide other functions aside from antibody generation. B 
cells are capable of secreting cytokines for cell signaling during infection and have been 
observed to release a diverse repertoire of signaling mediators that can both enhance or blunt the 
inflammatory response such as IL17 and IL10 respectively
164
. Cytokine production by B cells 
within the context of infection and autoimmunity is an ongoing field of interest
164, 165
. In addition 
to providing cytokine help, B cells have also been shown to be capable of presenting antigen to 
T-cells, thereby boosting local immune reactive processes in the case of infections or 
autoimmunity. Activated B cells have been shown to increase the expression of antigen 
presenting molecules such as MHC class II which allows for peptides to be presented to CD4
+
 T-
cells
157, 158
. However, antigen presentation by B cells is relatively inefficient compared to 
professional antigen presenting cells such as dendritic cells or macrophages. Furthermore, B cells 
can only boost the response towards cognate antigens but are unable to prime a response towards 
a novel antigen
166
.  
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3.2 GENERATION OF THE B CELL    
B cells are lymphocytes that develop within the bone marrow following interactions of the BCR 
with stromal cells present within the compartment
167
. The BCR is the primary signaling molecule 
that allows for B cells to detect and respond to antigen. During B cell development, the BCR is 
generated via gene rearrangement of germline DNA to generate receptors capable of recognizing 
a colossal range of antigenic targets, giving rise to multiple different clonal B cell populations
168-
170
. After eliminating self-reactive B cells, these immature B cells then migrate into circulation to 
begin patrolling for cognate antigen
171
. Upon binding with cognate antigen and receiving 
secondary activation signals via T-cell help or TLR signaling, B cells start proliferating and 
begin the process of somatic hypermutation
172
 and class switching to enhance BCR recognition 
and binding to cognate antigen. B cells also start terminally differentiating into plasma cells for 
the sole purpose of generating highly antigen specific antibodies
173, 174
.  
As mentioned, the BCR is responsible for antigen recognition by B cells against a diverse 
array of possible antigenic permutations
162
. This ability to recognize a diverse set of antigens is 
due to the process of gene arrangement of several segments of germline DNA coding for the 
BCR during B cell development within the bone marrow
168
. The colossal variability that arises 
from the possible permutation of the BCR gene segments allows for B cells to recognize any 
possible antigenic configuration that can be encountered by the host
175
.  
B cells develop within the bone marrow from progenitor B cells (pro B cell) which 
requires direct contact with IL7 secreting stromal cells for continued survival and proliferation. 
Interactions of the pro B cell with the stromal cell also induces the expression of DNA 
recombinases RAG1 and RAG2 which are required for gene arrangement
167, 168
.  
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Further development requires pro B cells to begin rearrangement of the immunoglobulin 
gene locus to generate the heavy chain portion of the BCR. Each pro B cell has two consecutive 
chances to rearrange the heavy chain (one on each chromosome) to generate a productive heavy 
chain. A functional heavy chain allows for continued survival of the pro B cells and generates 
signals that terminate further gene rearrangement on the heavy chain locus
170
.  
Upon successful rearrangement of the heavy chain, pro B cells are now classified as pre 
B cells. At this stage, the pre B cell undergoes multiple cell divisions to generate a clonal 
population of the same functional heavy chain. Each progeny cell would then begin 
rearrangement of the light chain locus, resulting in increased diversity of BCR arrangement from 
the same heavy chain. A productive light chain rearrangement results in the generation of an 
immature B cell bearing a functional BCR in the form of membrane bound IgM
176
. Immature B 
cells undergo negative selection within the bone marrow where self-reactive B cells are either 
eliminated via mIgM crosslinking after binding with cognate self-antigen
173
 or undergo further 
gene editing of the light chain locus
177
. The immature B cells that remain then exit the bone 
marrow compartment into circulation as naïve B cells, ready for activation upon recognizing 
cognate antigen. Typically, only around ten percent of B cells generated enter the pool of B 
lymphocytes circulating in the bloodstream
178
.  
3.3 B CELL ACTIVATION AND THE HUMORAL RESPONSE 
Most naïve B cells in the periphery never encounter their cognate antigen and therefore die by 
apoptosis within a few weeks
178
. B cell activation typically requires the two signals, antigen 
crosslinking of the BCR as the primary signal
160
 and T-cell help via CD40 and CD40L 
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interactions
179
. This mode of activation is known as thymus-dependent (TD) antigen activation. 
However, thymus-independent (TI) antigens are also present which do not require T-cell help but 
rely on multimeric BCR crosslinking by antigen. The mode and action of TI antigens are less 
complex and different than TD antigens, with TI antigenic responses being closer to those of the 
innate immune system
180, 181
.   
3.3.1 Induction of the humoral response. 
B cell activation typically occurs within lymph nodes and involves TD antigens. The 
lymphatic system drains excess tissue fluid from various tissues and is thus an ideal site for 
lymphocytes such as B cells to encounter antigen
174
.  
The binding of cognate antigen with the BCR results in the assembly of large signaling 
complexes on the surface of the B cell, involving various molecules such as CD19, CD21 and 
CD81, that results in the increased expression of MHC class II and costimulatory molecule B7 
on the B cell surface
162
. After BCR recognition and binding, the antigen is internalized via 
receptor mediated endocytosis, processed within the endocytic pathway and presented on the 
MHC class II molecules to recruit T-cell help. Once a corresponding T-cell recognizes the 
presented peptide, a T-B cell signaling conjugate is formed to facilitate further cellular 
interaction via CD40/CD40L and B7/CD28 interactions or cytokine release. This process 
typically occurs at the interface of the cortex and the paracortex of a lymph node which is rich in 
B cells and T-cells respectively
182-184
.  
Once antigen mediated B cell activation occurs, the activated B cell undergoes intense 
proliferation, forming a clonal population of B cells
185
. These B cells also begin to move further 
into the cortex, forming small foci of activated cells. Some of the activated B cells differentiate 
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into plasma cells within the foci to begin producing IgG and IgM antibodies which constitutes 
the primary antibody response
172
. These foci of cells are thought to migrate into the follicles 
present within the cortex of the lymph node which contains follicular dendritic cells (FDC). The 
follicular dendritic cells are uniquely suited for presenting antigen to B cells as they possess long 
cellular extensions with extensive Fc receptors and complement receptors, allowing for retention 
and presentation of antigen-antibody complexes over long periods on the cell surface
186
. The 
interaction of activated B cells with these FDCs is essential for further B cell activation, antibody 
class switching and differentiation into plasma cells
185
. 
3.3.2 Antigen induced B cell Differentiation. 
The migration of activated B cells into the follicles of the cortex eventually results in the 
formation of a germinal center, which are regions of intense B cell proliferation. Germinal 
centers are crucial structures in the course of B cell differentiation as these are sites where B 
cells undergo affinity maturation via somatic hypermutation of the BCR and antibody class 
switching. Formation of B memory cells and terminal differentiation into plasma cells also occur 
concurrently as B cells alter the BCR specificity
174, 185
. These structures are typically formed 
within the lymph node upon B cell encounter with antigen. However, within instances of chronic 
inflammation due to persistence of antigen, germinal centers can form ectopically within 
involved tissues
187
.         
Antibody affinity maturation describes the observation whereby the antigenic specificity 
of an antibody towards its cognate antigen in vivo increases significantly over time from the 
moment antigen is encountered. This observation was eventually attributed to somatic 
hypermutation, a process whereby activated B cells utilize the enzyme activation induced 
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deaminase (AID) to deliberately introduce random mutations specifically within the rearranged 
V(D)J segments of the immunoglobulin gene
188, 189
. The randomness of such mutations within 
the variable region of the immunoglobulin gene coupled with the high rates of cell proliferation 
allows for the B cell to modify the affinity of the BCR receptor to its cognate antigen
174, 185
.  
A selection mechanism is in place to direct somatic hypermutation, ensuring that the 
resulting BCR binds cognate antigen with greater affinity. Within germinal centers, FDCs take 
on the role of presenting antigen to B cells undergoing somatic hypermutation. Membrane BCR 
crosslinking of B cells by the antigen on the FDC permits continued B cell survival. Due to the 
miniscule amount of antigen present on the FDCs, only B cells that have higher affinity BCR for 
cognate antigen are successful in binding antigen and survive
186
. Upon binding antigen on the 
FDC, activated B cells need to be able to internalize the antigen and present them for T-cell help. 
The interaction with T helper cells by B cells is also an essential component for continued B cell 
survival
182
. After repeated process of somatic hypermutation and selection, subsequent B cells 
would have BCR far more efficient at antigen recognition and binding than the initial B cell that 
first encountered the antigen
185
.      
Activated B cells may further modify the BCR by altering the isotype of the heavy chain 
constant domain, a process termed antibody class switching. Class switching allows the antibody 
to retain its antigen recognition specificity but enables different biological effector activity 
depending on the heavy chain isotype. Class switching is thought to occur when the heavy chain 
DNA undergoes further rearrangement by a class of switch recombinase enzymes upon cytokine 
signaling
190-192
. CD40/CD40L interactions are also required for class switching to occur as 
patients with defects with CD40L on T-cells suffer from X-linked hyper-IgM syndrome. These 
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patients lack memory B cells, lack germinal centers and are only capable of generating IgM but 
not the other isotypes
193
.  
The humoral response to thymus dependent antigens relies very heavily on class 
switching from IgM to other antibody isotypes. To date, there are five known classes of antibody 
isotypes, IgM, IgD, IgG, IgA and IgE, each with well-defined biological roles regarding 
pathogen mediated responses
190
 (Fig. 3). 
 
Figure 3. B cell activation and differentiation into plasma cells upon antigen encounter. Adapted with permission 
from Macmillan Publishers Ltd: Nature Reviews Immunology
153
, copyright 2005. 
3.3.3 Antibody-mediated interactions.  
Antibodies mediate a wide range of immune activities against encountered antigen and by 
extension pathogens. As mentioned, the antibody isotype can specify for distinct effector 
functions but antibodies also elicit shared biological activities.  
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Antigen recognition by antibodies is a means for the immune system to tag and bind 
foreign matter for elimination via the formation of antibody antigen immune complexes
155, 156, 
158
. Binding of the Fc portion on antibodies of such complexes with Fc receptors on immune 
cells allow for targeted cytotoxic activities on antibody coated pathogens or cells via antibody-
dependent cell-mediated cytotoxicity (ADCC). This process involves the targeted delivery of 
lytic enzymes that kill antibody bound targets or can involve the delivery of apoptotic signals to 
antibody coated cells. ADCC is typically mediated by natural killer (NK) cells, macrophages and 
eosinophils. In the case of ADCC, antibodies function as receptors that direct clearance actions 
on bound targets
155
.  
IgE antibodies are primarily associated with the clearance of multicellular parasites and 
helminthes and allergic responses. IgE functions by priming nonphagocytic cells such as mast 
cells, basophils and eosinophils via the binding of Fcε receptors194, 195. Upon recognition of 
antigen, the prebound IgE on the Fcε undergoes crosslinking and receptor ligation, resulting in 
cell degranulation of vesicles loaded with inflammatory mediators such as TNF and leukotriene 
C4 along with proteins affecting vascular permeability such as histamine
196
.    
Antibodies are also capable of activating complement, a collection of serum 
glycoproteins with several different functions. Complement proteins, when properly activated, 
can perforate cell membranes leading to cell death. Byproducts of the complement activation 
cascade such as C3b can mediate antigen clearance by binding to the complement receptor on 
macrophages. Complement activation is primarily mediated by IgM and several subclasses of 
IgG in humans
157
. 
IgA antibodies are the main components of humoral immunity which protect mucosal 
surfaces such as the gastrointestinal and reproductive tract from pathogenic invasion. Circulating 
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IgA antibodies and those synthesized by plasma cells of the lamina propria in the gut are 
transported across the epithelial layer by polymeric immunoglobulin receptors (pIgR) expressed 
on the basolateral surface into the lumen
197
. Within the luminal space, IgA acts by binding and 
neutralizing pathogens and any pathogen derived toxins from causing direct damage to the 
epithelium
154
.  
Figure 4. Possible mechanism of action for antigen antibody complexes and FcγR receptors on various immune 
cells. Reused with permission from Macmillan Publishers Ltd: Nature Reviews Immunology
198
, copyright 2008. 
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Antibodies bound to antigen can also directly enhance phagocytosis by macrophages and 
neutrophils via opsonization. Due to the multimeric nature of antibodies, antigen antibody 
binding leads to the formation of immune complexes which agglutinates antigenic particles, 
allowing for more efficient clearance by phagocytic cells. Uptake of antibody bound complexes 
requires the crosslinking of Fc receptors present on macrophages and neutrophils to signal for 
phagocytosis
156, 158
 (Fig.4).  
3.3.4 Fc receptor biology.  
Each antibody isotype has its respective Fc receptor that binds to the Fc portion of the 
antibody
199, 200
. As mentioned above, these receptors allow the various antibody isotypes to elicit 
specific immunologic responses designed to enhance pathogen clearance. Fc receptors also allow 
for immune complexes to be internalized by antigen presenting cells to mediate further immune 
activation particularly for T-cell activation. Lastly, Fc receptors help to clear the extracellular 
environment of antigen to mediate anti-inflammatory responses after immune activation to 
prevent excessive damage to host tissue
52, 200, 201
.  
Fc receptors are typically members of the immunoglobulin superfamily and recognize the 
Fc portion of the heavy chain of each antibody isotype. Each Fc receptor has a distinct cell 
expression profile that corresponds to the specific biological activity of the antibody isotype. All 
Fc receptors require crosslinking and ligation of multiple receptors to initiate cell signaling. 
Receptor crosslinking is typically achieved by the association of Fc receptors with immune 
complexes as it contains multiple Fc ends that bind to multiple Fc receptors on the cell surface, 
initiating receptor ligation and cell signaling
52, 159, 201
.  
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Almost all Fc receptors, upon ligation, signal for immune activation except for FcγRIIB 
which negatively regulate cell activation upon recruitment and ligation. Fc receptors are fairly 
conserved between mouse and humans although humans have an expanded repertoire of 6 
activating FcγR members compared to the 4 found in mice. FcγRIIB is primarily found on B 
cells, plasma cells, macrophages, mast cells, and neutrophils and is thought to terminate cell 
activation upon recruitment into the Fc receptor signaling complex by immune complexes
201, 202
 
(Fig. 5.).  
 
Figure 5. Members of the FcγR receptor family of humans and mice. Reused with permission from Cambridge 
University Press: Expert Reviews in Molecular Medicine
52
, copyright 2009.  
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Cell activation by Fc receptor complexes depends on several factors which dictate the 
signaling context for the cell. These factors are the type and ratio of Fc receptor expressed on the 
immune cell, the extracellular microenvironment which the cell resides in and also the size of 
immune complexes present
198, 201-203
.  
As mentioned above, the presence of inhibitory FcγRIIB in the signaling complex 
impairs cell activation. Thus, a signaling complex with FcγRIIB would require a larger amount 
of other activating Fc receptors present within the complex to elicit cellular activation. The ratio 
of activating and inhibitory receptors present on the cell surface helps to illustrate the ease of 
activation for the particular immune cell upon ligation with antibody antigen immune 
complexes
52, 159, 198
.  
The extracellular microenvironment is a major determinant for Fc receptor activation 
thresholds as cytokines are able to influence the expression pattern of Fc receptors on immune 
cells such as macrophages and B cells. IFNγ has been shown to upregulate activating FcγRIIA 
and FcγRIII on macrophages while IL4 tends to increase FcγRIIB expression on the cell surface 
of macrophages but decrease FcγRIIB on B cells. Such responses towards cytokine signaling 
thus alters the activation inhibition ratio and hence, the activation threshold of specific immune 
cell lineages
52, 204
.  
Cellular activation can also be influenced by the size of the antibody antigen immune 
complex
205
. Large immune complexes are formed when there is an excess of antibody compared 
to cognate antigen while smaller immune complexes results from antigen excess. These large 
complexes are thought to possess more free Fc ends that can recruit more Fc receptors into a 
signaling complex on the cell surface. Thus, the probability of crosslinking FcγRIIB in a cell 
signaling complex is higher compared to interactions of smaller immune complexes with less Fc 
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ends, which favors cellular activation. Macrophages have been shown to respond differently 
when fed with immune complexes of varying sizes in vitro. Larger immune complexes tend to 
favor IL10 production by macrophages while smaller complexes tend to result in IL12 
production
206
. The different modes of cell behavior elicited by immune complexes of different 
sizes may be a means by which the immune system detects antigen concentration via antibodies 
and relay the appropriate response via Fc receptor recruitment depending on immune complex 
sizes. 
Fc receptors are also known to be cross-linked by pentraxins, a family of acute phase 
immune proteins such as serum amyloid P (SAP) and C reactive protein (CRP). Both examples 
are involved in innate immune recognition of bacterial and fungal pathogens and are capable of 
inducing complement activation
196, 197
. Hence, Fc receptors are a robust sensing system that 
allows immune cells to respond to cues from both the innate and adaptive arms of the immune 
system. 
3.4 THE ROLE OF HUMORAL IMMUNITY IN TUBERCULOSIS 
The humoral response has not been a focus of anti-tuberculous immunity. The intracellular 
nature of the pathogen, hiding within the phagocytotic cells, would logically render the 
immunogenic epitopes of the bacteria invisible to circulating antibodies. In any case, antibody 
binding is a mechanism to promote and enhance phagocytosis. Even with antibody recognition 
and binding to M. tuberculosis, such processes would only facilitate the entry of the pathogen 
into phagocytic cells to propagate infection
50
.  
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Historical attempts to develop passive immunization therapies against M. tuberculosis 
infection by introducing antisera from various animals into human patients provided inconsistent 
results ranging from no improvement to disease exacerbation, likely attributed to the different 
preparations of antisera for treatment
207
. As antibiotics were introduced and were found to be 
more effective as a treatment agent, interest in defining humoral immune responses against 
tuberculosis as a possible treatment modality began to wane
208
.  
 With the discovery of the T-cell arm of cellular immunity and the central role they play 
in neutralizing intracellular pathogens, scientific interests were more focused on defining the 
protective responses of T-cells rather than humoral components of tuberculosis immunity. As T-
cell responses such as IFNγ and TNF signaling pathways were characterized, humoral immunity 
against TB was not as actively pursued beyond defining antibodies as biomarkers to distinguish 
between active and latent infections
69, 84, 85, 88, 89, 135
. 
However, with recent findings of humoral immunity being capable of influencing antigen 
presentation, T-cell activation and macrophage activation phenotypes, there is renewed interest 
in defining the role of B cells and antibody in tuberculosis immunity. By better defining the role 
of humoral immunity towards M. tuberculosis, vaccine development can be enhanced by 
incorporating components that elicit specific modes of cellular activation better suited for dealing 
with intracellular pathogens such as M. tuberculosis or providing better readouts for correlates of 
protection. Furthermore, genetic variation pertaining to humoral immunity might very well 
influence individual risks of infection and disease outcome in terms of developing active and 
latent disease. Such findings are crucial as it can help identify populations at risk of infection or 
developing active disease which ultimately aids in providing better diagnosis and treatment
208-210
.  
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3.4.1 B cell contributions to tuberculosis control.  
The role of B cells and antibody in tuberculosis remains largely undefined compared to the 
contribution of T-cells towards disease control. Tissue sections from lung granulomas of infected 
animals or lung tissue resections of M. tuberculosis infected patients had B cells present within 
the site of the lesion
211, 212
. These observations suggest that B cells are activated and are 
trafficking into the granuloma. Further characterization of these B cells suggests that they are 
highly proliferative, via Ki67 staining, and express CD21, a marker of germinal center B cells, 
within the granuloma
213, 214
. These data further suggest that B cells appear to be forming ectopic 
germinal centers at the site of the infection. However, the precise mechanism of how B cells 
contribute towards M. tuberculosis containment is still undetermined.    
Cytokine production by B cells has not been characterized as extensively as T-cells 
although B cells are known to produce a variety of cytokines such as IL6 and IL10
164
. Indeed, 
the contribution of B cell cytokine production towards a variety of autoimmunity conditions such 
as multiple sclerosis is increasingly being recognized
165
. However, B cell cytokine production in 
infectious disease immunity is relatively unknown although B cells are known to influence 
cytokine production by other immune cells
164, 165
. In the context of tuberculosis, µMT mice 
lacking B cells were observed to have elevated IL10 production within infected lungs compared 
to infected wild type control mice. In addition, infected B cell depleted mice had substantial 
infiltration of neutrophils into the lungs, indicating that rampant inflammation is occurring. The 
massive inflammatory response was absent within µMT mice reconstituted with B cells from 
tuberculosis infected wild-type mice. This suggests that B cells are providing some amount of 
immunologic control towards tuberculosis infection
211, 215
. In humans, B cells were found to be 
able to alter IL17 and IL22 cytokine production of lymphocytes from pleural fluid of M. 
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tuberculosis infected patients in vitro
213
. Thus, B cells have an enormous capacity to alter the 
cytokine milieu at the site of infection either by providing signaling cues to other cells or by 
producing the cytokines themselves. 
3.4.2 Antibody contributions towards Tuberculosis control. 
Although antibody is a crucial component in immunity against pathogens, its contribution 
towards tuberculosis control is unknown. Many studies involving antibody attempted to identify 
possible antibody signatures within serum from human patients as potential biomarkers for 
diagnosing active and latent tuberculosis infection. Although certain M. tuberculosis antigens 
were identified as being very immunogenic in terms of inducing antibody titers, very few studies 
were done to elucidate the mechanism of action by antibody against the bacilli
207, 210
.  
What is known is that antibodies can alter macrophage microbial killing capacity as 
antibody coated M. tuberculosis is more readily killed after phagocytosis in vitro compared to 
uncoated bacilli. This suggests that the presence of antibody induces the bacilli to be taken up via 
a separate pathway, possibly via FcγR, leading to more bacterial killing50. In vivo experiments 
involving transfer of infected wild-type mice serum into infected µMT mice revealed that 
infected µMT did better with lower inflammation within the lungs when treated with infected 
mouse serum. These findings clearly delineate a role of antibody in regulating macrophage 
activation and tissue inflammatory reactions
215
.     
As mentioned previously, antibody interacts with the rest of the immune system via the 
Fc receptor family, particularly FcγR for IgG. FcγR has been implicated in a variety of 
autoimmune conditions and infections where variations within specific FcγR molecules are 
associated with susceptibility to systemic lupus erythematosus
203
 and malaria
52
. Findings of 
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tuberculosis infection in mice deficient in particular FcγR revealed similar susceptibilities 
towards tuberculosis infection; mice lacking in the inhibitory receptor FcγRIIb had less 
pathology in the lungs compared to both wild-type mice and mice lacking all activating FcγR216.  
Taken together, these findings suggest that antibodies are providing a certain degree of 
control over inflammatory processes that influences the outcome of tuberculosis infection, at 
least in mice. Humans and non-human primates have an expanded repertoire of FcγR compared 
to mice
52
. By understanding how anti-tuberculosis antibodies can manipulate immune cell 
activation, future vaccine candidates can be improved to maximize anti-microbial capacity of the 
immune system while ameliorating excessive inflammation to reduce tissue damage from 
bystander responses.     
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4.0  STATEMENT OF THE PROBLEM 
M. tuberculosis is an intracellular pathogen that is the causative agent of tuberculosis, affecting a 
third of the world’s population. 10 percent of infected individuals develop clinical symptoms of 
active tuberculosis while the remaining 90 percent are latently infected as they successfully 
contain the disease and remain clinically asymptomatic. In order to contain the bacilli, the host 
immune system forms an organized conglomeration of cells known as a granuloma. The 
granuloma is thought to function as a physical and immunological barrier, keeping M. 
tuberculosis contained by walling off infected macrophages at the center of the structure. 
However, the granuloma is a dynamic structure that depends on host-pathogen interactions to 
maintain itself. Failure to control the bacilli within the granuloma allows for bacterial 
proliferation and dissemination throughout the host resulting in reactivation within latent 
individuals. To date, the contribution of humoral immunity towards containing M. tuberculosis, 
particularly the role B cells and antibody, remains largely unknown.  
The cynomolgus macaque model of M. tuberculosis infection has been shown to 
recapitulate human tuberculosis very closely, allowing for the dissection of immunologic and 
microbiologic events during infection not possible in human infection. This model would thus 
permit us to examine the role of the humoral immune system in the contribution towards M. 
tuberculosis containment. The first aim of the study focuses on defining B cells present within 
the granuloma and examining the antibody content within infected tissue from the lung at 
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necropsy. We found that B cells are organizing into ectopic germinal centers within the 
lymphocytic cuff of the granuloma. Antibodies specific to M. tuberculosis antigens are also 
present at higher quantities within granulomatous tissue compared to normal lung. By 
understanding how the humoral immune system is organized within sites of infection, we can 
thus determine how B cells and antibody interact with other immune cells such as macrophages 
and T-cells to contain the infection.  
The second portion of the study focuses on examining how in vivo B cell depletion alters 
the course of infection within the non-human primate model of tuberculosis. B cell depletion was 
achieved using Rituximab, a chimeric monoclonal anti-CD20 antibody that is widely used in 
clinical cases of autoimmunity and lymphoma. B cells numbers were tracked throughout the 
course of the study to ensure adequate depletion within the peripheral and the lymphoid 
compartment. M. tuberculosis infected animals treated with saline were used as controls. We 
used tissue bacterial burden, disease presentation at necropsy, T-cell responses and tissue 
cytokine content as a basis of comparison between both B cell depleted and control groups. The 
findings from this study indicate no difference in the control of M. tuberculosis within the first 
10 weeks after infection with or without B cells. These findings address the second aim of the 
study in determining the effects of M. tuberculosis infection with B cell depletion. 
The third portion of the study looks at how macrophages behave in the absence of B cells 
and antibody. This part of the study aims to examine the content of two enzymes that specify for 
different modes of activation for macrophages, inducible nitric oxide synthase (iNos) for pro-
inflammatory macrophages and Arginase-1 (Arg1) for anti-inflammatory macrophages and how 
these enzymes are affected by levels of antibody within the granuloma.    
  
 38 
4.1 SPECIFIC AIM 1: DEFINE THE ROLES OF B CELLS WITHIN THE 
GRANULOMAS OF CYNOMOLGUS MACAQUES INFECTED WITH M. 
TUBERCULOSIS. 
Hypothesis: Granulomas of infected cynomolgus macaques have activated B cells and more 
antibodies specific to M. tuberculosis antigens relative to normal lung tissue  
Understanding how the humoral response organizes itself within the granuloma will 
allow for further investigation into the interaction of B cells and antibody along with other cells 
within the granuloma. 
4.2 SPECIFIC AIM 2: EXAMINING THE EFFECTS OF IN VIVO B CELL 
DEPLETION VIA RITUXIMAB IN M. TUBERCULOSIS INFECTED CYNOMOLGUS 
MACAQUES. 
Hypothesis: B cell depleted animals would have a worse disease outcome compared to infected 
control animals. 
B cells are hypothesized to be essential within the granuloma in terms of generating 
antibodies specific to M. tuberculosis and cytokines specifying for adequate cellular activation. 
By depleting B cells, granulomas are less able to organize an effective immune response in 
containing the bacilli. B cell depleted animals are hypothesized to present with more disease 
burden at necropsy compared to control animals.  
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4.3 SPECIFIC AIM 3: EXAMINING THE EFFECT ON MACROPHAGE 
ACTIVATION WITHIN THE GRANULOMAS OF B CELL DEPLETED ANIMALS. 
Hypothesis: Macrophages within granulomas of B cell depleted animals will have higher levels 
of Arg1. 
Antibodies are known to set the threshold of activation of macrophages via signaling 
through Fc receptor crosslinking. In the absence of antibodies, as in the case of B cell depleted 
animals, macrophages are hypothesized to be less capable of activation for bacterial killing via 
the production of iNos.  
 40 
5.0  ACTIVATED B CELLS IN THE GRANULOMAS OF NONHUMAN PRIMATES 
INFECTED WITH MYCOBACTERIUM TUBERCULOSIS 
This chapter is adapted from the original publication 
Phuah JY, Mattila JT, Lin PL, Flynn JL: Activated B cells in the granulomas of 
nonhuman primates infected with Mycobacterium tuberculosis, The American journal of 
pathology 2012, 181:508-514 
 
5.1 ABSTRACT 
In an attempt to contain Mycobacterium tuberculosis, host immune cells form a granuloma as a 
physical and immunological barrier. To date, the contribution of humoral immunity, including 
antibodies and specific functions of B cells, on M. tuberculosis infection in humans remains 
largely unknown. However, recent studies in mice have revealed that humoral immunity can 
alter M. tuberculosis infection outcomes. M. tuberculosis infection in cynomolgus macaques 
recapitulates essentially all aspects of human TB. As a first step to understanding the importance 
of humoral immunity to control of M. tuberculosis infection in primates, we characterized the B 
cell and plasma cell populations in infected animals and found that B cells are primarily present 
in clusters within the granuloma. The B cell clusters are in close proximity to PNAd
+
 cells and 
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contain cells positive for Ki67
+
, a proliferation marker. Granuloma B cells also express CXCR5 
and has elevated HLA-DR expression. Tissues containing M. tuberculosis bacilli had higher 
levels of M. tuberculosis specific IgG, compared to uninvolved tissue from the same monkeys. 
Plasma cells were detected within the granuloma, and produce mycobacteria-specific antibodies. 
Together these data demonstrate that B cells are present and actively secreting antibodies 
specific for M. tuberculosis antigens at the site of infection, including lung granulomas and 
thoracic lymph nodes. These antibodies likely have the capacity to modulate local control of 
infection in tissues. 
5.2 INTRODUCTION  
Mycobacterium tuberculosis (M. tuberculosis) is an intracellular pathogen that is the causative 
agent of tuberculosis (TB), an infection that is estimated to affect a third of the world’s 
population. Ten percent of infected individuals develop clinical symptoms of active TB while the 
remainder develops latent infection, which is clinically asymptomatic but can reactivate to cause 
active TB
217-219
. In response to M. tuberculosis infection, the host immune system forms an 
organized conglomeration of cells known as a granuloma. Granulomas are crucial in control of 
mycobacterial pathogens as they function as an immune and physical barrier to prevent 
widespread bacterial dissemination within the host
220
. Proper control of M. tuberculosis requires 
immune cells within the granuloma to kill internalized bacilli by activating macrophages while 
simultaneously balancing anti-inflammatory signals to reduce tissue damage. T-cells in particular 
play a critical role in activating macrophages via the release of interferon gamma (IFNγ) and 
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tumor necrosis factor (TNF)
83, 221
. The contribution of B cells to control of human M. 
tuberculosis infection and pathology remains unknown. 
Upon activation by antigen, mature B cells proliferate and differentiate into plasma cells 
for the sole purpose of generating antigen specific antibodies. Antibodies can affect host-
pathogen interactions by enhancing phagocytosis, antibody dependent cell cytotoxicity, and 
blocking pathogen-host receptor interactions
50, 52
. Antibody mediated phagocytosis can modify 
macrophage behavior depending on how the Fc portion of antibodies interact with the Fc 
receptors expressed on macrophages
206, 222
. B cells also present antigen to T-cells and enhance 
CD4
+
 antigen specific T-cell expansion
223
, 
224
. B cell depletion slows disease progression of what 
are predominantly T-cell mediated autoimmune conditions such as multiple sclerosis
225, 226
 and 
type 1 diabetes
227
 in mice and in humans. These studies reinforce the notion that B cell antigen 
presentation is capable of mediating further effects on T-cells to drive immune activation in the 
presence of antigen.   
As M. tuberculosis is primarily an intracellular bacillus, the contribution of humoral 
immunity to protection was thought to be minimal. Studies in the late 19th and early 20th 
centuries on the protective effects of passive immunization yielded conflicting results which 
have been attributed to antisera preparation
210
. M. tuberculosis infection of B cell deficient mice 
have also yielded variable findings ranging from increased pathology or bacterial burden to no 
apparent change in disease progression
211, 228
. The inconsistencies in these mouse studies make it 
difficult to ascertain the role of the humoral response against tuberculosis in humans. However, 
several studies have indicated that other components of the humoral response such as Fc 
receptors
216
, polymeric Ig receptors
229
 and IVIg
230
 can affect the outcome of M. tuberculosis 
infection in mice. These studies suggest that B cell responses can confer protection against M. 
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tuberculosis infection either directly or by modulating cellular immune responses such as 
macrophages, T-cell priming and activation.  
In the mouse model of M. tuberculosis infection, B cells are present in the lungs, often in 
aggregates that stain positive for PNA, reminiscent of germinal centers in lymph nodes
211, 231
. 
Some studies have suggested that granulomas may also function as tertiary germinal centers 
where the T-cell population is continuously activated via antigen presentation by B cells. B cell 
aggregates have been identified in human lung tissue from TB patients
212, 232
. However, how 
these B cell aggregates function in the context of M. tuberculosis control is still unknown.     
This study aims to determine the characteristics of B cells and plasma cells within the 
granulomas of M. tuberculosis-infected cynomolgus macaques. The NHP model of M. 
tuberculosis infection has been shown to mimic all aspects of human tuberculosis, particularly in 
granuloma type and structure.  
5.3 MATERIALS AND METHODS: 
5.3.1 Experimental animals 
Samples from 14 adult (>4 years of age) cynomolgus macaques (Macaca fascicularis) (Covance, 
Alice, TX; USA Valley Biosystems, West Sacramento, CA) experimentally infected with M. 
tuberculosis for other studies were obtained for the B cell studies described here. All animals 
were housed under BSL-3 conditions. These studies followed all animal experimentation 
guidelines and all experimental manipulations and protocols were approved by the University of 
Pittsburgh School of Medicine Institutional Animal Care and Use Committee.  
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5.3.2 M. tuberculosis infection 
Cynomolgus macaques were infected with 25-200 CFU Erdman strain M. tuberculosis via intra-
bronchial instillation as previously described
42, 43
. Infection was confirmed by conversion of 
negative to positive tuberculin skin test and elevated PBMC responses to mycobacterial antigens 
from baseline in lymphocyte proliferation (LPA) and ELISPOT assays
43, 233
. The tissues used for 
the studies described here were samples from M. tuberculosis infected control monkeys involved 
with other TB studies. 
5.3.3 Necropsy procedures 
Monkeys were maximally bled prior to necropsy and euthanized using pentobarbital and 
phenytoin (Beuthanasia; Schering-Plough, Kenilworth, NJ). Gross pathologic findings were 
described by a board-certified veterinary pathologist (EK) and were classified as previously 
described. Representative sections of each tissue were placed in formalin for histologic analysis 
or homogenized into single-cell suspensions for immunologic studies, flow cytometric analysis, 
and bacterial burden, as previously described
42, 43, 233
. Bone marrow was also obtained from the 
sternum by flushing exposed bone marrow with tissue grade 1xPBS (Lonza, Walkersville, MD) 
using a 20 gauge needle (BD, Franklin Lakes, NJ). Red blood cells were lysed using the BD 
Pharm Lyse buffer (BD Biosciences, San Diego, CA) according to manufacturer’s instructions 
prior to cell enumeration. Tissue homogenates from numerous necropsy samples were serially 
diluted and plated on 7H11 media (BD, Sparks, MD) and CFUs were enumerated on day 21. 
Lung samples with culturable M. tuberculosis were classed as ‘involved’ tissue (Inv) while 
samples with no cultivable bacteria were ‘non-involved’ (Unv). Lymph node tissues were 
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classified based on anatomical location with thoracic lymph nodes being lung-draining (dLN) 
and other lymph nodes being peripheral (pLN).  
5.3.4 Histologic analysis and immunohistochemistry 
Tissue sections were embedded with paraffin and stained with haemotoxylin and eosin (H&E). 
These sections were then reviewed microscopically by a veterinary pathologist (EK) with 
specific emphasis on granuloma characteristics as described previously
233
. Serial sections were 
used for immunohistochemistry staining of cell markers. Briefly, slides were processed in 
antigen retrieval buffer (Tris Base, 0.05% Tween 20, pH9) prior to staining. Antibodies used for 
staining were anti-human CD20 (rabbit polyclonal, Neomarkers, Fremont, CA), anti-human CD3 
(rabbit polyclonal, Dako, Carpinteria, CA), anti-human Ki67 (rabbit polyclonal, Neomarkers, 
Fremont, CA), anti-mouse peripheral node addressin (PNAd) (clone MECA-79, Biolegend, San 
Diego, CA), anti-rhesus CXCR5 (mouse monoclonal, NIH Nonhuman Primate Reagent 
Resource, Boston, MA), anti-human CD138 (clone MI5, Neomarkers, Fremont, CA) and 
biotinylated peanut agglutinin (PNA) (Vector, Burlingame, CA). Cell nuclei were stained with 
DRAQ5 (Biostatus Limited, Shepshed, UK). Slides were preserved using Prolong Gold with 
DAPI (Invitrogen, Carlsbad, CA) prior to being visualized with an Olympus Fluorview 500 
upright confocal laser scanning microscope (Model BXL21). 
For plasma cell detection, fresh tissues were fixed in freshly prepared 4% 
paraformaldehyde for 6 hours at 37°C, washed with 1xPBS (Lonza, Walkersville, MD), and 
dehydrated in sucrose solution (30% sucrose, 1xPBS) overnight at 4°C. The tissue was then 
frozen with cold isobutanol in liquid nitrogen. The frozen tissue was embedded in Tissue-Tek 
O.C.T. compound (Sakura Finetek, Torrance, CA) and 8µm sections were cut using a cryostat 
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microtome (Microm International, model HM505N) at -20°C. Sections were placed on gelatin 
coated slides and air dried overnight at 37°C. The slides were then stained directly as described 
above.           
5.3.5 Flow cytometry analysis of surface markers and quantification of B cells 
within tissue 
Single cell suspensions were derived from granulomatous lung, normal lung, pulmonary draining 
lymph nodes and peripheral lymph nodes. Cells from these tissue samples were stained for T-
cells using anti-human CD3 (clone SP34-2, BD Biosciences), B cells using anti-human CD20 
(clone 2H7, eBioscience) and T-cell costimulatory molecules CD86 (clone 2331, BD 
Pharmingen) and HLA-DR (clone LN3, eBioscience). Lymphocytes were identified based on 
size (FSC) and granularity (SSC). B cells and T-cells were further identified based on CD20
+ 
and 
CD3
+
 expression, respectively. Further characterization for HLA-DR and CD86 were carried out 
within the CD20
+
 population. B cell numbers within tissue were calculated by multiplying the 
percentage of CD20
+
, percentage of lymphocyte population from flow cytometry, with total cell 
numbers obtained from tissue homogenate and normalizing to tissue weight.  
5.3.6 Intracellular cytokine staining of B cells within tissue 
Single cell suspensions derived from granulomatous lung and pulmonary draining lymph node 
were stimulated with RPMI (Lonza, Walkersville, MD) supplemented with 1% L-glutamine and 
1% HEPES (Sigma, St. Louis, MO) containing M. tuberculosis CFP10 and ESAT6 proteins (BEI 
Resources, Manassas, VA) along with Brefeldin A (BD Biosciences), all at a final concentration 
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of 1µg/ml for 4 hours. After staining for CD20 as described above, cells were then fixed and 
permeabilized using BD Cytofix/Cytoperm (BD Biosciences) and finally washed with BD 
Perm/Wash buffer (BD Biosciences). Cells were then stained using anti-human antibodies 
against IL2 (clone MQ1-17H12, BD Biosciences), IL6 (clone MQ2-6A3, BD Biosciences), IL10 
(clone JES3-9D7, eBiosciences), IL17 (clone eBio64CAP17, eBiosciences), TNFα (clone 
MAb11, eBiosciences) and IFNγ (clone B27, BD Biosciences). All cytokine producing B cells 
were identified from the CD20
+
 gate.  
5.3.7 IgG ELISA 
Supernatants obtained from tissue homogenates (granulomatous lung, normal lung, pulmonary 
draining lymph nodes and peripheral lymph nodes) after necropsy were used to quantify total and 
M. tuberculosis specific IgG. Tissue culture grade 96 well flat bottom plates (Costar, Corning, 
NY) were coated with 2μg of M. tuberculosis culture filtrate protein (CFP) or mouse anti-primate 
IgG (clone 8F1, NIH Nonhuman Primate Reagent Resource, Boston, MA) dissolved in tissue 
grade PBS (Lonza, Walkersville, MD) and incubated overnight at 4°C. 1% bovine serum 
albumin (BSA) in PBS was used to block the plates either at room temperature for 2 hours or 
overnight at 4°C. Samples were plated in duplicate and serial dilutions were performed at 1:2 
with 1% BSA in PBS. Standard curves were generated using purified cynomolgus macaque 
serum IgG. Horseradish-peroxidase conjugated mouse anti-primate IgG antibody (clone 1B3, 
NIH Nonhuman Primate Reagent Resource) was used as the detection agent, diluted at 1:5000. 3, 
3’, 5, 5’-tetramethylbenzidine hydrochloride (Sigma, St. Louis, MO) was used as the 
chromogenic substrate according to manufacturer’s instructions. All incubations were performed 
for 1 hour at 37°C unless otherwise stated. All washes were performed with 1x PBS.       
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5.3.8 Plasma cell ELISPOT 
96 well ELISPOT plates (Upstate Millipore, Billerica, MA) were coated with M. tuberculosis 
CFP, ESAT6 protein (BEI Resources, Manassas, VA) and mouse anti-primate IgG (clone 8F1, 
NIH Nonhuman Primate Reagent Resource, Boston, MA) and blocked as described above. Cells 
from tissues obtained during necropsy (bone marrow, granulomatous lung, normal lung, 
pulmonary draining lymph nodes and peripheral lymph nodes) were resuspended to 1x10
6
/ml in 
RPMI (Lonza, Walkersville, MD) supplemented with 1% L-glutamine and 1% HEPES (Sigma, 
St. Louis, MO). 1.5x10
5
 cells (150μl) were added into each well and were incubated for 16-20 
hours at 37°C. Horseradish-peroxidase conjugated mouse anti-primate IgG antibody (clone 1B3, 
NIH Nonhuman Primate Reagent Resource, Boston, MA) was used as the detection agent, 
diluted at 1:2500 and incubated for 1 hour at 37°C. Each well was developed using 100μl of 3-
Amino-9-ethyl-carbazole (AEC) prepared according to manufacturer’s instructions (Vector, 
Burlingame, CA). All washes were performed with 1x PBS.     
5.3.9 Data analysis 
Flow cytometry data was analyzed with the FlowJo software package (Tree Star, Ashland, OR). 
Data were analyzed using Prism 5 (Graphpad Software, San Diego, CA). Fluorescent whole 
granuloma images are composites of 20 to 40 images taken at 20x magnification and assembled 
with Adobe Photoshop 7 (Adobe, San Jose, CA). Statistical comparisons were performed using 
Mann-Whitney test with p<0.05 considered statistically significant. Paired samples were 
analyzed using the Wilcoxon matched-pairs signed rank test with the same threshold, p<0.05 as 
being statistically significant.  
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5.4 RESULTS 
5.4.1 Lung granulomas of NHPs contain aggregates of B cells reminiscent of 
germinal centers  
Serial sections of NHP lung granulomas were characterized histologically then stained for CD3, 
to identify T cells, CD20 for B cells, and DRAQ5 for cell nuclei. Scattered cells and aggregates 
of CD20
+
 cells were observed within the lymphocyte cuff of lung granulomas. CD3
+
 T-cells 
assumed a more ubiquitous distribution within the granuloma compared to the clustered 
appearance of CD20
+
 B cells and were observed to be closely associated within the B cell 
clusters. However, CD3
+
 T-cells were also present closer to the center of the granuloma, which 
was devoid of CD20
+ 
cells (Fig 6.). 
 
Figure 6. CD20
+
 B cells are present within the granuloma as clusters. A solid granuloma with some caseum and a 
small mineralized focus was stained for CD3 (green), CD20 (red) and nuclei (blue) to show the distribution of 
immune cells and with respect to granuloma morphology (H&E). These images show that CD20
+
 B cells and CD3
+
 
T-cells are found primarily within the lymphocytic cuff (yellow boxes in merged image). B cells generally form 
clusters but are also present as discrete cells, while T-cells are usually dispersed (top row). All images are 
composites of 20 to 40 images taken at 20x or 40x magnification. 
 
We hypothesized that the B cell clusters within the granulomas may be similar to ectopic 
germinal centers. To determine whether the CD20
+ 
clusters have tertiary germinal center 
characteristics
212
, we stained for PNA expression (germinal center B cells)
187, 234
, anti-human 
Ki67 (proliferation) and PNAd (high endothelial venules) [Fig. 7A]. Within a mature germinal 
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center, Ki67
+
 cells tend to cluster at the center of the B cell follicle to delineate actively 
proliferating cells (Fig. 7B). Ki67
+
 nuclei were detected within the lymphocytic cuff, indicating 
that active cellular proliferation was occurring. Cells with Ki67
+ 
nuclei were observed within the 
CD20
+
 B cell clusters in the granuloma but occurred only as isolated cells rather than a distinct 
cluster (Fig. 7C) compared to mature B cell germinal centers.     
 
Figure 7. CD20
+
 B cell clusters within macaque granulomas have germinal center characteristics. A) A caseous 
granuloma section with a mineralized core (H&E) was stained for CD20 (red), PNAd (green) and Ki67 (blue) to 
identify B cells, high endothelial venules and proliferating cells, respectively. Two CD20
+
 clusters were imaged in 
detail for germinal center markers (yellow boxes, top left). B) This image depicts a mature BALT cluster exhibiting 
prominent Ki67 staining within CD20
+
 cells in close association with high endothelial venules (yellow arrow), 
reminiscent of B cell follicles within lymph nodes. C) This image depicts B cell clusters within the lymphocytic cuff 
of the granuloma, containing some Ki67
+
 nuclei with some sporadic PNAd staining 
 51 
PNAd is important for lymphocyte chemotaxis and positive expression is associated with 
the presence of high endothelial venules which is indicative of germinal centers (Fig. 7C). 
PNAd
+
 cells were detected in close proximity to CD20
+
 cells within the lymphocytic cuff of the 
granuloma (Fig. 7C).  
Despite PNA being widely used in identifying germinal centers in the mouse models, no 
PNA staining was noted within the CD20
+ 
clusters of NHP granulomas, but strong PNA staining 
was noted within the macrophage layers of the granuloma. Very weak PNA staining was present 
within the B cell follicles of NHP lymph nodes (data not shown). PNA has also been described to 
stain human monocytes, macrophages and plasma cells
228
 (and unpublished data). These findings 
suggest that PNA expression is very different in primates compared to mice, and thus we 
excluded this as a germinal center marker. Thus, these data support that the CD20
+ 
clusters in 
granulomas display some prominent characteristics of ectopic germinal centers. Further 
characterization of the B cells within the granuloma was performed to assess cellular activation. 
5.4.2 5.4.2. CD20+ cell clusters within lung granulomas contain activated B cells 
Flow cytometry was performed on single cell suspensions of lung and lymph node tissues to 
assess B cell numbers within infected tissue. Lymphocytes were identified based on size and 
granularity while B cells were further isolated based on CD20
+
 expression (Fig. 8A). CD20
+
 
cells were found to be present at higher numbers within M. tuberculosis-infected lung compared 
to randomized normal lung samples on a per gram basis (p<0.005). No difference in CD20
+
 cell 
numbers were observed between lung draining (thoracic) lymph nodes (dLN) and peripheral 
lymph nodes (pLN) (Fig 8B).  
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Figure 8. Mycobacteria-containing tissue contains activated B cells. A) Lymphocytes were gated based on size 
(FSC) and granularity (SSC). B cells were further identified based on CD20
+
 expression. The FACS plot shown 
depicts the cellular profile of a lymph node sample. B) B cell numbers in lung and lymph node samples were 
expressed as B cells per gram tissue. Each point represents one tissue sample from one macaque. Error bars denote 
S.E.M. C) HLA-DR expression by CD20
+
 cells from lung draining lymph nodes (dLN) although slightly elevated, 
were not statistically significant compared to peripheral lymph nodes (pLN), n=7. Error bars represent S.E.M. D) 
Analysis of tissues from 2 representative macaques (19808 and 20908) however, showed that HLA-DR expression 
is elevated within CD20
+
 cells of lung dLN compared to pLN of the same macaque. CD20
+
 from involved lung 
samples also stained positive for HLA-DR. Normal lung lacks sufficient B cell numbers for analysis. E) Staining for 
CD3 (blue), CD20 (red) and CXCR5 (green) was done to determine if B cell clusters within the granuloma behave 
as ectopic germinal centers. CXCR5 was used to identify lymphocytes that are actively homing towards lymphoid 
tissue to identify germinal center reactions. Most of the B cell clusters stained positive for CXCR5 (yellow arrows), 
indicating that the CD20
+
 cells are activated and are capable of homing towards lymphoid tissue. 
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Increased HLA-DR expression on B cells was used to identify activated B cells within 
infected tissue on the premise that activated B cells have enhanced antigen presentation capacity. 
The frequency of CD20
+
 cells from thoracic or peripheral lymph nodes expressing HLA-DR was 
similar (Fig. 8C). However, HLA-DR expression was higher on CD20+ cells from thoracic 
compared to peripheral lymph nodes within individual animals, 19808 and 20908 (Fig. 8D). 
Although HLA-DR was demonstrated on cells from involved lung tissue, it was not possible to 
obtain similar data from “uninvolved” lung, as there were insufficient B cells present within 
those tissues to perform meaningful analysis. No appreciable difference in CD86 expression 
could be seen within the CD20
+
 cells from involved lung samples compared to uninvolved lung 
tissue (data not shown).       
The chemokine receptor, CXCR5 was used to identify activated lymphocytes that 
respond to trafficking signals into lymphoid tissue. CXCR5 expression was observed on CD20
+
 
B cell clusters within the granuloma. However, very little co-localization of CD3 and CXCR5 
was observed within the lymphocytic cuff of the granuloma, (Fig. 8E). 
5.4.3 Plasma cells and the antibody responses to M. tuberculosis specific antigen 
within involved tissues 
As the B cell clusters within the granuloma share many germinal center characteristics, the 
presence of plasma cells would further support the hypothesis that B cells are differentiating in 
situ of the granuloma. Plasma cells were identified within the granuloma based on morphology 
(“clock-faced” nuclei, higher cytoplasm to nuclei ratio) from H&E stained granuloma sections 
(Fig. 9.). CD138 (a plasma cell marker in humans) staining was performed on PFA fixed frozen 
granuloma sections but failed to detect any CD138
+
 plasma cells (data not shown). NHP lymph 
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node samples do contain cells stained positive with CD138 within the B cell follicles (data not 
shown).  
 
Figure 9. Granulomas contain plasma cells. Plasma cells with classical histologic features including clock-faced 
nuclei, perinuclear huff and higher cytoplasm to nuclei ratio, were identified within macaque granulomas (yellow 
arrows). 
As another measure of plasma cells, a short-term IgG ELISPOT was used to assess CFP 
and ESAT6 specific plasma cells within lymph node, lung and sternum bone marrow samples 
from 7 infected NHPs. Antigen specific plasma cells for mycobacterial antigens [culture filtrate 
proteins (CFP) and ESAT6] within involved lung samples and for CFP within lung dLN were 
higher on average compared to uninvolved lung samples and pLN, respectively, despite not 
achieving statistical significance. However, lung dLN did contain statistically higher numbers of 
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ESAT6 specific plasma cells compared to pLN, p<0.05 (Fig. 10A). Numbers of plasma cells 
specific for CFP and ESAT6 were comparable to each other within sternum bone marrow 
samples (Fig. 10B).  
 
Figure 10. Plasma cells within the granuloma secrete mycobacteria-specific IgG. A) Lung and lymph node samples 
were used in a plasma cell ELISPOT assay to quantitatively assess numbers of IgG secreting plasma cells specific 
for CFP and ESAT6, n=7. Each point represents one sample from one macaque. Some groups have less than 7 
points because insufficient cells were obtained to perform the ELISPOT. Significantly more ESAT6 specific plasma 
cells were detected within lung dLN compared to pLN (*p<0.05). ESAT6 specific IgG plasma cells within lung 
samples appear to be higher within inv lung but were not statistically significant. B) Both CFP and ESAT6 IgG 
specific plasma cells within bone marrow from the sternum were similar. Error bar denotes S.E.M. 
 
To quantitate antibody levels within tissue samples, lung and lymph node supernatants 
from 14 NHP were assayed by ELISA for CFP specific IgG antibodies. Pairwise analysis of 
involved and uninvolved lung samples from the same NHP also showed an increase in CFP 
specific IgG amounts within involved lung supernatants, p<0.05. The same increase was 
observed within lung dLN supernatants compared to pLN samples, p<0.01 (Fig. 11.). Total IgG 
levels were comparable within both lung and lymph node groups (data not shown). 
 56 
 
Figure 11. Granulomas contain more CFP specific IgG. A pairwise comparison of CFP-specific IgG in tissue 
supernatants was done using ELISA. Each data point represents a single sample from one macaque (n=14). Each 
line represents a paired sample of uninvolved lung (unv) and involved lung (inv) or pLN and lung dLN. Involved 
lung or lung dLN contained higher levels of CFP-specific IgG when compared to uninvolved lung (*p<0.05) and 
pLN (**p<0.01), respectively. Error bars denote S.E.M. 
5.4.4 CD20+ cells within the granuloma produce an assortment of cytokines 
The capacity of B cells to produce cytokines after encounter M. tuberculosis antigen was also 
assessed by flow cytometry. B cells from lung granulomas or lung dLN were stimulated with 
ESAT6 and CFP10 protein and stained for IL2, IL6, IL17, IL10, TNF and IFNγ. Cells were 
deemed positive for cytokine after comparison with media stimulated control samples (Fig. 12.). 
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Figure 12. Gating strategy to identify CD20
+
 cells that produce IL2, IL6, IL10, IL17, TNF and IFNγ. 
 
 
Figure 13. B cells are capable of producing cytokine within sites of infection. Primary cytokines produced by B 
cells are IL10, IL6 and IL17. Lung granulomas from 6 animals are depicted in this figure and differentiated by color. 
Each point denotes one sample 
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The major cytokines being produced by B cells within the granuloma are IL17 and IL6, 
both pro-inflammatory cytokines capable of encouraging TH17 T-cell development and 
neutrophil recruitment. A modest percentage of B cells are also producing TNF and IFNγ, 
around 1.6% and 2.5%, respectively.  Approximately 3.5% of B cells are also producing IL10, a 
cytokine associated with anti-inflammatory activity which strongly suggests that B cells are also 
capable of regulating inflammation within the granuloma. IL2 does not appear to be a major 
cytokine being generated by B cells (Fig. 13.).  
Multifunctional cytokine analysis revealed that B cell cytokine secretion of particular 
cytokines fall into distinct patterns. B cells either secrete IL6 or IL17 or both cytokines together. 
A very small subset of B cells secretes only IL10 alone but a larger proportion of IL10 secretion 
occurs with both IL6 and IL17 (Fig. 14A). When TNF and IFNγ secretion is included in the 
study, the same cytokine secretion behavior is observed within B cells. IL6 appears to be the 
main cytokine being produced and is associated with both pro-inflammatory cytokine secretion 
(TNF and IFNγ in various combinations) and anti-inflammatory IL10. IL10 secretion seems to 
only be secreted either alone, or in some combination with IL6 or any other cytokine. A small 
percentage of B cells (a median of around 1%) was observed to secrete TNF and IFNγ alone 
(Fig. 14B). 
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Figure 14. Multifunctional analysis of cytokine combinations produced by B cells within the granuloma. A) 
Multifunctional B cell analysis for IL6, IL10 and IL17 for 3 animals as differentiated by color. B) Multifunctional B 
cell analysis for IL6, IL10 and TNF and IFNγ for 6 animals as differentiated by color. Each point denotes one 
sample. 
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5.5 DISCUSSION 
The importance of B cells in control of human M. tuberculosis infection remains unclear, 
although numerous studies on antibody responses in humans have been published
210, 235, 236
. Here 
we assessed the presence of B cells and antibodies in the granulomas of M. tuberculosis-infected 
macaques, using a model that accurately recapitulates both the pathology (including granuloma 
types) and infection outcomes seen in humans infected with M. tuberculosis. B cells have been 
demonstrated to contribute to control of M. tuberculosis in mouse models
211
 and being 
reminiscent of germinal centers of lymphoid tissues based on cell organization and chemokine 
response
231
. However, the structure of murine granulomas is not similar to granulomas seen in 
humans. We demonstrate that B cells are present as a significant population within NHP lung 
granulomas, and are organized into discrete clusters with germinal center characteristics and 
numerous plasma cells and activated B cells.  
Several studies have suggested that B cells within the granuloma are highly reminiscent 
of germinal centers based on surface marker expression
212, 213
. Ectopic germinal center formation 
or lymphoid neogenesis has been closely associated with chronic inflammation in autoimmune 
and infectious disease settings
187
 and was considered a more efficient way of presenting antigen 
to drive cellular activation at lesion sites. In the case of the NHP granuloma, the B cell clusters 
may be positioned within the lymphocytic cuff evenly, analogous to the black spots on a white 
soccer ball. This may help drive antigen presentation for T-cell activation given the similarities 
of granuloma B cell clusters to lymph node germinal centers and the increased HLA-DR 
expression present on involved lung B cells.  
The findings of B cells within the granuloma producing IL17 and IL6 combined with the 
germinal cluster distribution of B cells within the granuloma indicate strongly that B cell clusters 
 61 
are capable of providing a microenvironment that encourages T-cell activation. The cytokine 
data in this study also support findings in both humans and mice infected with M. tuberculosis 
that implicate B cells as possible regulators for neutrophil recruitment
213, 215
, although the exact 
mechanism of control is still unknown. Further functional analysis may determine the ability of 
B cells from granulomas to present mycobacterial antigens and activate T-cell responses, as well 
as the relative efficiency of granuloma B cells for these processes compared to peripheral B cells 
mechanism of neutrophil recruitment beyond IL17 production. 
The cytokine secretion profile of B cells suggests that the predominant cytokine produced 
is IL6, either alone or in various combinations with other cytokines. This fits the observation in 
other fields on the pro- and anti-inflammatory nature of IL6 such as the ability to induce Th17 or 
Treg differentiation
237
 and also attest to the plastic nature of B cells in modulating 
inflammation
165
. IL6 production by B cells feature prominently in T cell dominant autoimmune 
conditions such as multiple sclerosis
164, 238
 where IL6 produced by B cell is suspected to amplify 
T cell responses via interactions within the lymph node. However, with the observation that B 
cells are forming ectopic germinal centers and the predominant cytokine produced by B cells 
within the granuloma is IL6, it is very likely that these tertiary lymphoid structures within the 
granuloma serve as a means to enhance T cell responses within the granuloma. One caveat is that 
IL6 producing B cells contribute significantly to pathology in certain cases of autoimmunity
238
. It 
remains unknown the extent of contribution provided by B cell cytokine production in 
tuberculosis control or induction of pathology. 
IL17 is the other another major cytokine being produced by B cells aside from IL6. This 
is in line with observations in human granulomas where B cell clusters within the granuloma are 
associated with elevated levels of IL17 and IL22
213
. However, in B cell depleted mice infected 
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with M. tuberculosis, elevated neutrophils were noted along with increased lung inflammation 
which suggests that there is a defect in mechanisms that regulate neutrophil recruitment and 
activation, of which IL17 and IL22 are involved. IL17 is invariably tied to Th17 cells which in 
the case of M. tuberculosis infected mice, can contribute towards the recruitment of Th1 T cells 
essential for control of tuberculosis
239
. The specific contribution by B cells in terms of IL17 
mediated immune response in primate tuberculosis is still unknown but may be closely related in 
neutrophil recruitment and function based on evidence from the mouse models
208, 211, 215
 and 
observations in human clinical tuberculosis cases
208, 211, 213, 215
.  
The B cell cytokine secretion profile also suggests that activated B cells can be separated 
into distinct subsets based on cytokine secretion patterns. As mentioned, IL6 is predominantly 
secreted by B cells either alone or in combination with other cytokines as discussed above. IL10 
however, appears to either be secreted alone or in the presence of multiple pro-inflammatory 
cytokines such as IL6 and IL17 or IFNγ and TNF. This suggests that IL10 secretion can be used 
to identify a subset of regulatory B cells or after B cells have acquired multifunctional cytokine 
secretion capacity, indicating prolonged activation. The idea of distinct B cell effector function 
has been proposed in mouse models of B cell activation
164
. Within the granuloma, B cells receive 
cytokine cues from T cells and could possibly differentiate into distinct effector and regulatory B 
cell populations based on their respective cytokine secretion profiles. Thus, the contribution of B 
cells in granuloma function may be significant both in terms of containing the bacilli and 
reducing tissue damage.   
The increased amount of antigen specific IgG at the site of infection lends support to the 
notion that antibody may modulate the host-pathogen interactions in the granuloma. Antigen 
specific IgG secreting plasma cells present within lung granulomas suggest that substantial 
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antibody production is occurring. However, a much greater increase of both antigen specific IgG 
and plasma cells was noted within lung draining lymph nodes which indicates that M. 
tuberculosis specific plasma cells are being generated and possibly retained within lung draining 
lymph nodes. These lymph nodes are often infected, and usually contain M. tuberculosis-specific 
T cells
42, 43
. It is very possible that the plasma cells in involved lung tissues are derived from 
activated B cells that are recruited to the granulomas. Upon fully differentiating into plasma 
cells, these terminally differentiated B cells likely gain CD138 expression and migrate back to 
the bone marrow. This would explain the absence of CD138
+
 cells within the granuloma. 
Although B cell clusters within the granuloma share many characteristics similar to lymph node 
germinal centers, granuloma B cell clusters contain far fewer B cells, making it less likely to 
detect mature CD138
+ 
expressing cells.    
The role of antibody remains unclear in tuberculosis. Historically, passive immunization 
and serum therapy has yielded conflicting results in human patients. Studies in humans have 
mostly been confined to using M. tuberculosis specific antibodies as indicators of disease states 
by measuring serum IgG specific to M. tuberculosis antigens
235, 236, 240
. However, there may be a 
role for antibodies at the site of infection. One proposed hypothesis is that antibody-coated 
(extracellular) M. tuberculosis bacilli engage Fcγ receptors (FcγR) rather than just DC-SIGN and 
complement receptors, resulting in increased macrophage activation
50, 241
. These changes are 
suspected to be mediated by crosslinking of Fcγ receptors expressed on macrophages and 
neutrophils by immune complexes of IgG and M. tuberculosis bacilli. Data from M. tuberculosis 
infected Fcγ receptor knockout mice also suggest that antibody mediated events are involved in 
the anti-tuberculosis response
216
.  Given that macrophage activation is essential for control of M. 
tuberculosis, antibodies may play a role in regulating macrophage function within the 
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granuloma. However, antibody mediated phagocytosis may not necessarily be protective, as 
demonstrated in dengue fever or Coxsackie B
222
. In rabbits infected with M. tuberculosis, 
increased B cell activation was observed to be associated with failure to contain the disease
242
. 
Antibody dependent enhancement of infection may also play a role in exacerbating the course of 
infection for M. tuberculosis. 
Our findings here demonstrate that activated B cells, plasma cells, and antibodies are 
enriched within the granuloma, and have some characteristics of germinal centers. Further 
studies will focus on defining the protective, pathologic or immune modulatory roles for these 
cells in tuberculosis.  
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6.0  THE EFFECTS OF B CELL DEPLETION IN MYCOBACTERIUM 
TUBERCULOSIS INFECTED CYNOMOLGUS MACAQUES  
6.1 ABSTRACT 
The role of B-cells and antibody in the control of M. tuberculosis remains largely unexplored. 
Although recent studies in mice have shown that components of humoral immunity can affect M. 
tuberculosis pathology and inflammation, the role of these components in human and non-human 
primate infections remain unknown.  The cynomolgus macaque model of M. tuberculosis 
infection closely mirrors the infectious outcomes in human tuberculosis. To begin to address the 
contribution of the humoral immune system in control of tuberculosis, we used anti-CD20 
antibody (Rituximab) to deplete B cells within a cohort of six cynomolgus macaques prior to M. 
tuberculosis infection and monitored them for ten weeks post infection. Although B cell follicles 
and M. tuberculosis specific antibodies were markedly diminished, no discernible differences in 
overall pathology or bacterial burden were observed between Rituximab treated animals and 
saline controls at 10 weeks post infection. Cytokine levels within lung granulomas as assessed by 
IFNγ ELISPOT, FACs and ELISA were also comparable between Rituximab treated and saline 
control groups. Taken together, our data suggests that both B cells and antigen specific antibody 
are not required for control of early M. tuberculosis infection.  
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6.2 INTRODUCTION 
The relative contribution of B cells and antibody towards the control of tuberculosis in humans 
or non-human primates remain relatively unknown. Data from B cell or FcγR-depleted mouse 
models of tuberculosis suggest that components of the humoral immune system do play a role in 
regulating disease pathology. This is evident from the excessive inflammation and neutrophilia 
found within lungs of M. tuberculosis infected μMT mice (no B cells)211 and Fc common γ chain 
deficient mice (no functional activating FcγR signaling)216. Passive transfer of infected mice sera 
into M. tuberculosis infected μMT mice is capable of reducing both lung inflammation and 
reversing neutrophilia
211, 215
. Furthermore, bacilli coated with M. tuberculosis antigen specific 
antibody were noted to induce greater killing by cultured macrophages in vitro
222
, suggesting that 
antibody mediated signaling is capable of enhancing the killing capacity of macrophages against 
internalized bacilli.  
This study aims to explore the effects of B cell depletion in the cynomolgus macaque 
model (Macaca fascicularis) of tuberculosis. B cell depletion in non-human primates can be 
achieved by the administration of anti-human CD20 chimeric monoclonal antibody, 
Rituximab
243
. Rituximab is in clinical use for the treatment of certain B cell lymphomas and 
autoimmunity conditions such as lupus, rheumatoid arthritis and multiple sclerosis. B cells are 
thought to be depleted via antibody dependent cell cytotoxicity modes of clearance by natural 
killer cells
244
. Although Rituximab use can predispose patients towards certain infections, the 
risk associated with its use in susceptibility to M. tuberculosis infection or reactivation is 
unknown
245
. 
Rituximab has been used in nonhuman primate research, particularly in animal models 
utilizing simian immunodeficiency virus (SIV) and is thus known to be effective at depleting 
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nonhuman primate B cells
243
. Although B cells are depleted, Rituximab has not been observed to 
interfere with the plasma cell compartment, since these cells are not generally CD20
+
. Hence, the 
antibody component of the humoral response would not be affected by Rituximab although 
further antigen specific antibody generation would be impaired. This study was undertaken to 
help elucidate the contribution of functional B cells and antigen specific antibodies on the control 
of tuberculosis. Such findings would allow for potential enhancement of future vaccine 
development or development of novel treatment modalities involving B cells or antibody. 
6.3 MATERIALS AND METHODS  
6.3.1 Experimental animals and B-cell depletion 
12 adult (>4 years of age) cynomolgus macaques (Macaca fascicularis) (Covance, Alice, TX; 
USA Valley Biosystems, West Sacramento, CA) were obtained for the B cell studies described 
here. The 12 animals were divided into 6 pairs where 1 animal receives Rituximab and the other 
receives saline as a control and are infected at the same time. 
Rituximab (Genentech, San Francisco, CA) was administered at a dosage of 50 mg/kg 
over a period of 45 minutes with the first dosage given 2 weeks prior to M. tuberculosis 
infection. Subsequent doses of Rituximab were administered every 3 weeks until the study 
termination at 10 weeks post infection. Control animals received saline infusion at the same time 
as the Rituximab counterparts within the pair.  
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All animals were housed under BSL-3 conditions. These studies followed all animal 
experimentation guidelines and all experimental manipulations and protocols were approved by 
the University of Pittsburgh School of Medicine Institutional Animal Care and Use Committee.  
6.3.2 M. tuberculosis infection 
 Cynomolgus macaques were infected with a low dose of approximately 4 to 8 CFU Erdman 
strain M. tuberculosis via intra-bronchial instillation as previously described
42, 43
. Infection was 
confirmed by conversion of negative to positive tuberculin skin test and elevated PBMC 
responses to mycobacterial antigens from baseline in lymphocyte proliferation (LPA) and 
ELISPOT assays
43, 233
.  
6.3.3 Necropsy procedures 
Monkeys were maximally bled prior to necropsy and euthanized using pentobarbital and 
phenytoin (Beuthanasia; Schering-Plough, Kenilworth, NJ). Gross pathologic findings were 
described by a board-certified veterinary pathologist (EK) and were classified as previously 
described. Representative sections of each tissue were placed in formalin for histologic analysis 
or homogenized into single-cell suspensions for immunologic studies, flow cytometric analysis, 
and bacterial burden, as previously described
42, 43, 233
. Bone marrow was also obtained from the 
sternum as previously described
214
. A portion of tissue homogenate from numerous necropsy 
samples were serially diluted and plated on 7H11 media (BD, Sparks, MD) and CFUs were 
enumerated on day 21, while the rest were filtered using 0.45 micron syringe filter units 
(Millipore, Darmstadt, Germany) for downstream assays. 
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6.3.4 Immunologic analysis 
Blood was drawn from each animal every 2 weeks starting 2 weeks prior to the first dose of 
Rituximab administration until necropsy at 10 weeks post infection. Peripheral blood 
mononuclear cells (PBMCs) were isolated as previously described via percoll gradient 
centrifugation
42
. Axillary and inguinal lymph nodes were biopsied prior to the first dose of 
Rituximab administration and then at weeks 4 and 8 post infection. 
6.3.5 Flow cytometry 
At necropsy, single cell suspensions were derived from lung granulomas, uninvolved lung and 
thoracic draining lymph nodes. Cells from PBMCs and tissue samples were stained for T-cells 
using anti-human CD3 (clone SP34-2, BD Biosciences), CD4 (clone L200, BD Biosciences) and 
CD8 (clone DK25, Dako), B cells using anti-human CD20 (clone 2H7, eBioscience) and CD79a 
(clone HM47, BD Pharmingen), neutrophils with CD11b (clone ICRF44, BD Pharmingen) and 
calprotectin (clone MAC387, Thermo Scientific) and co-stimulation marker HLA-DR (clone 
LN3, eBioscience). Lymphocytes and neutrophils were identified based on size (FSC) and 
granularity (SSC). B cells and T-cells were further identified based on CD20
+ 
and CD3
+
 
expression, respectively. Neutrophils were identified from CD11b
 
and calprotectin expression.  
For intracellular cytokine staining, tissue single cell suspensions were stimulated in 
RPMI (Lonza, Walkersville, MD) supplemented with 1% L-glutamine and 1% HEPES (Sigma, 
St. Louis, MO) containing M. tuberculosis CFP10 and ESAT6 proteins (BEI Resources, 
Manassas, VA) along with Brefeldin A (BD Biosciences), all at a final concentration of 1µg/ml 
for 4 hours. After staining for CD3, CD4, CD8 and CD20 as described above, cells were then 
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fixed and permeabilized using BD Cytofix/Cytoperm (BD Biosciences) and finally washed with 
BD Perm/Wash buffer (BD Biosciences). Cells were then stained using anti-human antibodies 
against IL2 (clone MQ1-17H12, BD Biosciences), IL6 (clone MQ2-6A3, BD Biosciences), IL10 
(clone JES3-9D7, eBiosciences), IL17 (clone eBio64CAP17, eBiosciences), TNF (clone MAb11, 
eBiosciences) and IFNγ (clone B27, BD Biosciences). All cytokine producing cells were 
identified as described above. 
6.3.6 IFNγ and plasma cell ELISPOT 
ELISPOT assays were performed as previously described
42
  with 1.5x10
5
 PBMC per well using 
ELISPOT reagents with known cross reactivity against macaque IFNγ (MabTech, Mariemont, 
OH)
233
. M. tuberculosis antigens used in ELISPOT were peptide pools (overlapping 20 mers; 
10μg/ml) from CFP10, ESAT6 and Rv1196 obtained from Sigma-Genosys (Woodlands, TX). 
Phorbol 12, 13-dibutyrate (PDBu) and ionomycin (50 nM and 10 μM final concentration 
respectively; Sigma) were used as positive controls. Media-only wells were used as negative 
controls. Cells in ELISPOT assays were incubated with antigens for two days at 37°C and 5% 
CO2 prior to being developed. All conditions were performed in duplicate wells. Plasma cell 
ELISPOTs were performed as previously described
214
 using bone marrow from sternum. 1.5x10
5 
bone marrow cells were added into each well. Plates were read using an ELISPOT plate reader 
(Cellular Technology LTD, Cleveland, OH). All ELISPOT data were expressed as SFU per 10
6
 
cells. 
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6.3.7 Antibody, cytokine and calprotectin ELISA 
ESAT6 and Rituximab specific antibodies were quantified via ELISA by coating 96 well plates 
with 2μg per well of ESAT6 whole protein (BEI Resources, Manassas, VA) or Rituximab 
(Genentech, San Francisco, CA) dissolved in 1x PBS (Lonza, Walkersville, MD). Undiluted 
filtered tissue homogenates were incubated for 1 hour at 37°C after blocking for ESAT6 
antibody quantification. Serum samples diluted to 1:100 using 1x PBS containing 1% BSA were 
used to assess for anti-Rituximab antibodies. Mouse anti-primate IgG conjugated to HRP (clone 
1B3, NIH Nonhuman Primate Reagent Resource, Boston, MA) were used as the detection 
antibody at 1:3000 dilution. Plates were developed using 3, 3’, 5, 5’-tetramethylbenzidine 
hydrochloride (Sigma, St. Louis, MO). CFP specific IgG and total IgG present within tissue 
homogenates were quantified as previously described
214
. 
Cytokine ELISAs were also performed to quantify for IL6, IL17, TNF and IL10. Anti-
human IL10 (Invitrogen, Carlsbad, CA), TNF, IL6, and anti-primate IL17 ELISA kits (MabTech, 
Mariemont, OH) were performed according to manufacturer’s instructions using filtered tissue 
homogenates obtained at necropsy as samples.  
All quantifications for cytokine or antibody amounts were calculated on a per granuloma 
basis. All data from pertaining to lymph nodes were normalized to the weight of the lymph node 
in milligrams. 
6.3.8 Immunohistochemistry  
Tissue sections were embedded with paraffin and stained with haemotoxylin and eosin (H&E). 
These sections were then reviewed microscopically by a veterinary pathologist (EK) with 
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specific emphasis on granuloma characteristics as described previously
233
. Paraffin embedded 
slides of relevant tissue sections were stained as previously described
214
 for the presence of T 
cells (CD3), B cells (CD20) and antigen presenting cells (CD11c). Images were taken at 20x 
magnification and serial images were used to generate a composite of the tissue section. 
6.3.9 PET/CT scans 
All PET/CT scans were performed in a biosafety level 3 imaging suite using a hybrid preclinical 
PET/CT system that includes a micro-PET Focus 220 preclinical PET scanner (Siemens 
Molecular Solutions, Knoxville, TN) and an 8-slice helical CT scanner (Neurologica Corp., 
Danvers, MA) as previously described
133
. 
6.3.10 Data analysis and statistics. 
Flow cytometry data was analyzed with the FlowJo software package (Tree Star, Ashland, OR). 
Data were analyzed using Prism 6 (Graphpad Software, San Diego, CA). All data are shown as 
medians to account for the variability of the data. Statistical comparisons were performed using 
Mann-Whitney test with p<0.05 considered statistically significant. Paired samples were 
analyzed using the Wilcoxon matched-pairs signed rank test with the same threshold, p<0.05 as 
being statistically significant. Multivariate analysis and linear correlations were performed using 
JMP 10 (SAS, Cary, NC).   
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6.4 RESULTS 
6.4.1 Rituximab depletes B cells of non-human primates within the blood and 
tissue compartments 
Rituximab was administered 2 weeks prior to M. tuberculosis infection to ensure that B cell 
numbers were minimal upon infection. Subsequent doses of Rituximab were given every 3 
weeks to ensure continued B cell depletion over the course of the study. We confirmed that B 
cells were successfully depleted within treated animals over the course of infection by following 
B cell percentages within the peripheral and lymphoid compartments. B cell depletion was 
successfully achieved within all 6 treated animals with no treatment failure. PBMCs from 
biweekly blood draws and single cell suspension from monthly peripheral lymph node biopsies 
were stained with anti-human CD20 and an alternative intracellular marker, CD79a to identify B 
cells. CD79a was used as an alternative B cell marker to independently confirm B cell depletion 
in the event that Rituximab interferes with CD20 staining via flow cytometry. Animals given 
Rituximab had almost no B cells in the peripheral compartment and reduced B cells within 
lymphoid tissue compared to saline control animals (Fig. 15.).  
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Figure 15. Confirmation of B cell depletion with Rituximab treatment. Depletion of CD20
+
 and CD79a
+ 
cells within 
the peripheral and lymphoid compartment of treated NHP (red) and saline control NHP (blue) after administration of 
Rituximab (Black arrows). Infection with M. tuberculosis occurs 2 weeks after the first dose of Rituximab (Red 
arrow). The study runs for a total of 12 weeks with necropsy at 10 weeks post infection (Red X). A total of 12 NHPs 
are used in the study, 6 per group. The solid line depicts group mean and individual animals are represented by the 
fainter dotted lines. 
 
At necropsy, single cell suspension of tissue samples similarly stained with CD20 and 
CD79a antibodies showed markedly reduced B cell numbers within lung granulomas (median B 
cell percentage of 0.8% in Rituximab group compared to 6% in saline control animals, between 1 
to 9 samples per animal, N of 6 per group) of Rituximab animals. Thoracic lung draining lymph 
node samples of Rituximab treated animals also showed a similar depletion in B cells (median B 
cell percentage of 0.6% compared to 10% of saline control animals) compared to animals 
receiving saline. These data were confirmed with a similar decrease seen with CD79a staining, 
an alternative pan B cell marker (Fig. 16.).   
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Figure 16. Confirmation of B cell depletion within lung granulomas and thoracic lymph nodes (LN) of Rituximab 
treated animals. Rituximab treatment also depletes B cells within the tissue compartment as seen in samples 
obtained at necropsy. Rituximab treated animals (red) showed substantial decrease in CD20
+
 and CD79a
+
 
lymphocyte percentages compared to control animals (blue) within lung granulomas and thoracic lymph nodes. 
 
Immunohistochemistry staining of lung granuloma from Rituximab treated animals 
showed reduced numbers and size of B cell aggregates compared to granulomas of saline control 
animals (Fig. 17.). B cell follicles were also similarly reduced within lymph node sections of 
treated animals as compared to control lymph nodes. This confirms that Rituximab treatment was 
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successful in reducing the B cell population of treated cynomolgus macaques for the duration of 
the study. 
 
Figure 17. Confirmation of B cell depletion via immunohistochemistry imaging. Immunohistochemistry staining of 
paraffin embedded sections of lung granuloma and lymph node from Rituximab treated animals showed reduced B 
cell clusters within lung granulomas and B cell follicles within lymph nodes. Samples from treated animals and 
saline controls were stained with anti-human CD3 (blue) for T cells, CD11c (green) for myeloid or APCs, and CD20 
(red) for B cells    
6.4.2 B cell depletion is accompanied by a reduction in antibody levels within lung 
and lymphoid tissue but not serum antibody levels 
Tissue homogenates prepared from lung granuloma and thoracic lymph node samples were used 
to quantify the amount of M. tuberculosis specific IgG (CFP and ESAT6) and total IgG present 
using ELISAs. Lung granulomas of Rituximab treated animals showed significantly lower 
amounts of IgG specific for the mycobacterial antigen mixture CFP or the ESAT6 protein of M. 
tuberculosis and total IgG (Fig. 6.4.). Similarly, lymph node samples from Rituximab treated 
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animals had lower amounts of CFP specific antibody and total IgG compared to lymph nodes 
from saline control animals (Fig. 18.). 
 
Figure 18 B cell depletion is accompanied by reduction in thoracic lymph node tissue IgG levels. CFP specific and 
total IgG was reduced within lymph node samples of Rituximab treated animals. 
 
 
Figure 19. B cell depletion did not affect plasma cell compartment. Plasma cell numbers within the bone marrow is 
unaffected within animals of both groups. Each point represents one tissue sample obtained from a total of 12 
animals.    
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However, there was no difference in numbers of plasma cells present within the bone 
marrow of the sternum (Fig. 19.), which suggests that Rituximab depletion did not affect the 
plasma cell compartment at least over the course of the study. Furthermore, quantification of 
serum samples suggests that levels of CFP specific IgG and total IgG in serum were not different 
overall between animals from B cell depleted groups versus saline control animals, although 
significant variation in serum antibody content were noted within individual animals from both 
groups (Fig. 20.).  
 
Figure 20. Serum antibody levels of CFP specific IgG and total IgG were similar to saline control sera. Serum 
samples from Rituximab treated animals did not show any differences in the levels of CFP specific IgG or total IgG 
compared to saline control animals. Dotted lines represent individual animals and solid lines represent group 
averages with Rituximab animals in red and saline control animals in blue. 
 
Although Rituximab depletes B cells, the process of depletion within the lymphoid tissue 
was not complete and some B cells were noted to still be present. Quantification of anti-
Rituximab antibodies undertaken to ensure that over the course of treatment, anti-Rituximab 
responses were not generated such that it would interfere with process of B cell depletion. 
Analysis of serum antibodies specific for Rituximab showed that B cell depleted animals as a 
group did not mount any notable response to Rituximab since the levels of antibody binding to 
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Rituximab in the serum is comparable to samples from control group animals. This suggests that 
the amount of anti-Rituximab antibodies were not different from background as saline control 
animals did not receive any Rituximab (Fig. 21.). 
 
Figure 21. Anti-Rituximab antibodies were not generated within B cell depleted animals . Levels of anti-Rituximab 
antibody within the sera of Rituximab treated animals were not different compared to sera obtained from saline 
control animals. This suggests that anti-Rituximab antibodies were not being generated within B cell depleted 
animals. 
 
These data demonstrate that B cell depletion within Rituximab treated animals was also 
accompanied by a reduction in antibody levels within infected tissue but not in serum. However, 
existing plasma cells that generate antibody were unaffected. Furthermore, B cell depleted 
animals are not mounting any responses to Rituximab that would hinder the process of B cell 
depletion. 
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6.4.3 Clinical findings of M. tuberculosis B cell depleted animals 
Prior to necropsy, PET/CT scanning using [
18
F]-FDG was performed to assess disease 
progression within the lungs and thoracic lymph nodes and provide a “roadmap” for harvesting 
lesions at necropsy. Both Rituximab and saline control animals were found to have 
approximately the same number of granulomas on scan, with a median of 19 granulomas (range 
of 11 to 24 granulomas per animal) within the Rituximab group and 18 granulomas (range of 11 
to 24 granulomas per animal) for saline controls (Fig. 22.). 
 
Figure 22. PET/CT identification of lung lesions. No differences were seen in terms of granuloma numbers as 
identified by PET/CT scans. 
 
At necropsy, the gross pathology findings of each animal were used to compile necropsy 
scores. This score takes into account the pathological findings including s number of granulomas 
within each lobe, extent of lymph node involvement, disease dissemination within the lungs or 
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presence of extrapulmonary disease. Animals within the Rituximab group generally displayed 
the same amount of disease as monkeys within the saline control group, with similar necropsy 
scores (Fig. 23.). This suggests that disease progression at 3 months post infection was 
comparable with little difference in terms of gross pathology between B cell depleted animals 
and control animals.  
 
Figure 23. Necropsy score assessment of animals. Clinical disease presentation at necropsy, translated as a necropsy 
score to reflect disease dissemination and general body condition, showed no difference between B cell depleted 
animals and saline controls. 
 
Previous studies on B cell deficient mice infected with M. tuberculosis showed severe 
neutrophil infiltration into the lungs of μMT mice and elevated IL10 amounts. Granulomas from 
Rituximab treated animals did not display excessive neutrophilic infiltrate compared to 
granulomas from control animals. The only noted difference was a marked reduction in the 
lymphocytic cuff of Rituximab treated granulomas (Fig 24.).  
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Figure 24. Histological assessment of lung granuloma slides. Histological assessment of lung granulomas revealed 
no overt differences in terms of granuloma appearance aside from a paucity of lymphocytic cells as expected from B 
cell depleted animals compared to saline controls. 
 
Homogenates from numerous (more than 50) tissue samples from each monkey at 
necropsy were plated on 7H11 agar to assess bacterial burden. After 3 weeks, the plates were 
counted to determine bacterial burden for each tissue sample. Bacterial burden for lung 
granulomas were compiled from each animal to determine the overall bacterial burden within 
each group. Rituximab animals have a slightly statistically significantly higher overall bacterial 
burden on a per granuloma basis (Rituximab animals have 0.5 log units higher in bacterial 
burden compared to saline controls, p=0.01) compared to saline controls. No difference in 
bacterial burden was seen within the thoracic lymph node samples, with both groups displaying a 
median bacterial burden around 100 colony forming units (Fig. 25.).  
A CFU scoring system was used to assess for overall bacterial burden within an animal, 
taking into account of all samples including extrapulmonary and non-granulomatous samples. 
The median CFU score of Rituximab treated animals were not statistically different from the 
median CFU score of saline controls (saline group median score at 115, Rituximab group median 
score at 148, p=0.3, Fig. 26.).  
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Figure 25. Bacterial CFU assessment of lung granulomas and thoracic lymph nodes. Bacterial burden within 
individual lung granulomas, normalized to per granuloma and from thoracic lymph nodes were performed by plating 
tissue homogenate on 7H11 agar and read 3 weeks later. A statistically significant higher bacterial CFU was 
observed within lung granulomas of B cell depleted animals (median difference of 0.5 log units, p=0.01) compared 
to saline controls. Bacterial burden within the thoracic lymph nodes were comparable within both groups of animals. 
Each dot represents one sample from one animal with a total of 12 animals. 
 
 
Figure 26. CFU score of animals to assess overall bacterial burden. Overall bacterial burden within an animal was 
assess using a CFU score calculated by taking into account of all bacterial CFU counted in all the collected samples 
from each animal at necropsy. CFU scores of B cell depleted animals (median score of 148) and saline control 
animals (median score of 115) were not statistically significant (p=0.30). Each dot represents one animal with a total 
of 12 animals, 6 per group. 
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The percentage of sterilized granulomas with no bacterial growth on 7H11 agar were not 
significantly different in samples from both groups (7.85 percent for saline control versus 5.69 
percent in Rituximab samples, p=0.92, Fig. 27.). Lung granuloma samples from individual 
animals were found to have either no bacteria or up to 10
6 
bacterial present (Fig. 28.) which 
reflects the granuloma variability within individual animals and between animals.  
 
Figure 27. Granuloma sterilization efficiency assessment. This figure depicts the percent of granuloma samples that 
did not have any bacterial CFU on 7H11 agar after 3 weeks of incubation. These samples are termed sterile due to 
the absence of any M. tuberculosis bacteria recovered. Granulomas from saline controls and B cell depleted animals 
were not statistically different in the percent of sterile granulomas (p=0.99). Each dot represents one animal with a 
total of 12 animals, 6 per group. 
 
 
Figure 28. Variation of granuloma CFU within individual animals. This graph depicts the range of bacterial burden 
within lung granulomas of animals from B cell depleted group (red) and saline controls (blue). Each dot represents 
one sample from the respective animals from a total of 12 animals, 6 per group. 
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6.4.4 T cell responses within non-human primates were unaffected by B cell 
depletion 
 
Figure 29. T cell percentage of live cell assessment. Median lung granuloma CD3, CD4 and CD8 percentage of 
lymphocytes were found to be lower (p<0.001 for both CD3 and CD4 percentages and p<0.005 for CD8 
percentages) within B cell depleted animals compared to saline counterparts. Each dot represents one lung 
granuloma from one animal from a total of 12 animals, 6 per group. 
 
Single cell suspensions from tissue samples obtained at necropsy were analyzed by cell surface 
and intracellular cytokine staining for flow cytometry to assess for T cell numbers and cytokine 
production. CD3, CD4 and CD8 percentages were statistically lower within lung granulomas of 
the Rituximab treated animal (p<0.05) for CD3, CD4 and CD8 percentage of lymphocytes, 
indicating that fewer T cells were present within lung granulomas in the absence of B cells (Fig. 
29.). This is confirmed by enumerating actual CD3 counts and normalizing to tissue weight of 
the respective tissue. Lung granuloma samples from Rituximab treated animals have a lower 
median of CD3
+
 cells compared to saline control granulomas (Fig. 30.).      
 86 
 
Figure 30. CD3
+
 T cell enumeration of granuloma samples from Rituximab treated and saline control animals. 
Rituximab treated animals had a lower median of CD3
+
 T cells within the granuloma (by about 0.5 log units) 
compared to saline control granulomas, p<0.01. Each dot represents on granuloma sample from one animal from a 
total of 12 animals, 6 per group. CD3
+
 T cell numbers were normalized to tissue weights expressed in milligrams 
(mg tissue). 
 
T cell cytokine secretion profiles were also assessed in lung granuloma samples for the 
percentages of T cells making IL2, IL17, TNF or IFNγ in response to ESAT6 and CFP10 
peptides. No difference in T cell cytokine production was observed in lung granulomas, except 
for IL2, within Rituximab treated animals and saline controls. The percentage of IL2 producing 
T cells was slightly elevated (p=0.058) within samples from B cell depleted animals for lung 
granulomas (Fig. 31.). A similar pattern was observed in thoracic lymph nodes of Rituximab 
animals, with only elevation of IL2 producing T cells compared to saline controls. 
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Figure 31. T cell responses within B cell depleted animals are largely unaffected aside from IL2 production. 
Cytokine secretion by CD3 cells as measured by intracellular cytokine FACs showed no difference in IFNγ, TNF or 
IL17 production. A trend of slightly increased IL2 secretion was observed within B cell depleted animals compared 
to saline controls (p=0.058). Each dot represents one lung granuloma from one animal from a total of 12 animals, 6 
per group. 
 
Enumeration of cytokine secreting CD3
+
 T cells within the lung granuloma samples were 
performed to confirm the cytokine secreting T cell percentages within the lung granuloma 
samples. The numbers of CD3
+
 T cells secreting IL2, IL17 and TNF were not statistically 
significant although there was a trend that Rituximab treated animals had lower numbers of 
cytokine secreting T cells within the granuloma compared to saline controls. However, the 
number of IFNγ secreting T cells was statistically lower within Rituximab treated granulomas 
compared to saline controls indicating that less T cells secreting IFNγ was present (Fig. 32.). 
 88 
  
Figure 32. Cytokine secreting CD3
+
T cells were enumerated and normalized according to tissue weights. Although 
not statistically significant, the number of T cells secreting IL2, IL17 and TNF were slightly lower within Rituximab 
treated granulomas compared to saline control samples. IFNγ secreting T cells, however, were statistically lower 
within Rituximab treated granulomas compared to saline controls indicating that there were less IFNγ secreting T 
cells present at the site of infection within B cell depleted animals. Each dot represents one lung granuloma from 
one animal from a total of 12 animals, 6 per group. 
.   
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6.4.5 Immunological readouts within the granuloma are similar between 
Rituximab and control groups      
To assess for the presence of neutrophils, a calprotectin ELISA was performed as a surrogate 
readout for neutrophils
246
. Levels of calprotectin per granuloma were not significantly different 
between Rituximab treated and saline control animals (Fig. 33.), suggesting that neutrophils are 
obviously impaired in recruitment or function. 
 
Figure 33. Quantification of calprotectin protein levels within lung granulomas. A calprotectin ELISA was 
performed using lung granuloma homogenates as a means to measure neutrophil presence. No difference was seen 
between B cell depleted and control animals for calprotectin amounts, p>0.99. Each spot represents one lung 
granuloma sample. 12 animals, 6 per group were represented here.  
 
IFNγ ELISPOT responses to CFP, and ESAT6 and Rv1196 peptides were assessed using 
lung samples that were culture positive for M. tuberculosis. No difference in numbers of IFNγ 
secreting cells were seen between B cell depleted and control group animals in response to these 
mycobacterial antigens (Fig. 34.).  
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Figure 34. IFNγ ELISPOT analysis of lung granuloma cells in response to M. tuberculosis antigens. IFNγ 
ELISPOTS to assess for cytokine release upon stimulation with CFP, M. tuberculosis antigens ESAT6 and Rv1196 
showed that responses were comparable within lung granuloma samples from B cell depleted animals and saline 
control group. 
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Figure 35. ELISA data for cytokine quantification within lung granuloma homogenates. Cytokine ELISAs to assess 
for IL6, IL10, IL17 and TNF amounts within lung granuloma homogenates of animals of both groups also revealed 
no significant differences for all cytokines chosen. Each spot represents one lung granuloma sample. 12 animals, 6 
per group were represented here. Open circles indicate interpolated sample values that fell below the lowest 
detectable limit as measured from the standard curves of the respective assays.  
 
Cytokine ELISAs were performed to assess for levels of IL10, IL17 and TNF in an effort to 
identify any differences in pro- or anti-inflammatory cytokines within granulomas. A great 
degree of variability was observed in terms of cytokine content within the granuloma 
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homogenates obtained from one animal and between animals, consistent with other studies we 
have performed in this model. Granuloma homogenates from Rituximab treated animals were 
not statistically different in terms of cytokine content for these cytokines compared to granuloma 
homogenates obtained from animals in the saline control group with the exception of IL6. 
Median IL6 content within B cell depleted granulomas were almost significantly lower than 
saline control granuloma homogenates (p=0.08), indicating that there is a trend of lower IL6 
within the granuloma as a result of B cell depletion (Fig. 35.). 
6.4.6 Correlative studies on granuloma cytokine content 
Quantification data of cytokines, cell composition and bacterial burden of individual granulomas 
were used from either B cell depleted or saline control animals to assess for correlations between 
parameters. This analysis was performed to identify any differences in the correlative 
interactions between the various cytokine components, T cell percentages, antibody content and 
bacterial numbers (Table 1.). Within saline control granulomas, IL10 levels positively correlated 
with IL17 levels (R
2
=0.76) and IL6 levels positively correlates with bacterial burden (R
2
=0.61). 
However, these relationships were different within granulomas from the B cell depleted group 
where IL6 correlates poorly with bacterial burden (R
2
=-0.08) [Fig. 36.] and IL10 does not 
correlate with IL17 (R
2
=-0.23) [Fig. 37.]. Thus B cell depletion seems to influence the interplay 
of cytokines, cell percentages and bacterial burden in the granuloma. These differences may hint 
at changes in cell behavior that could produce significant changes in longer term B cell 
depletion. 
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Table 1. Analysis of correlations between various cytokines, calprotectin, CFU, T cell composition and antibody 
content for individual granulomas of the Rituximab treated group and saline controls. The boxed correlation values 
were noted to be different within granulomas from saline control animals versus B cell depleted animals. R
2
 values 
were confirmed to be significant following a non-parametric Spearman’s ρ analysis (Appendix A, Tables 2. and 3.).  
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Figure 36. Linear correlation analysis of granuloma IL6 content to bacterial burden. The graph depicts the levels of 
IL6 within a granuloma and its corresponding bacterial burden. A linear correlation was performed to note the 
relationship between these two variables. R
2
 values for Rituximab granulomas were -0.084 compared to 0.607 for 
saline controls, indicating that the relationship of IL6 and bacterial burden was different from granulomas of B cell 
depleted animals. Each point represents one granuloma from one animal from a total of 6 animals per group.  
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Figure 37. Linear correlation analysis of granuloma IL10 content to granuloma IL17 content. The graph depicts the 
levels of IL6 and IL10 within granulomas from B cell depleted and saline control animals. A linear correlation was 
performed to note the relationship between these two cytokines. IL10 was noted to be negatively correlated with 
IL17 within B cell depleted granulomas but being positively correlated with IL17 in saline control granulomas. This 
suggests that cytokine expression within B cell depleted granulomas is markedly different compared to saline 
controls. Each point represents one granuloma from one animal from a total of 6 animals per group.    
 
6.5 DISCUSSION 
The goal of this study was to determine whether B cell depletion affects the outcome of M. 
tuberculosis infection within non-human primates. B cell depletion was achieved by treatment 
with repeated administration of anti-CD20 antibody (Rituximab), while control animals were 
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treated with saline. The choice of saline as a control was made, since administering NHP IVIg 
could result in serum sickness
230, 247, 248
. The duration of the study was for a total of 12 weeks 
with 2 initial weeks of B cell depletion prior to infection with M. tuberculosis. The infection 
period of 10 weeks was used due to signs of adverse reactions to Rituximab infusion 
(anaphylaxis) getting progressively worse in some animals, meaning that B cell depletion states 
could not be safely maintained and thus necessitates the short study period of 10 weeks post 
infection. The cause of anaphylaxis is unknown but is unlikely to be due to Rituximab based on 
the lack of anti-Rituximab antibodies being generated. Furthermore, any B cells that do respond 
to human antibody epitopes are likely to be depleted anyway with further Rituximab 
administration. A likely explanation could be that the lysing of B cells during the depletion 
period releases pro-inflammatory mediators systemically, resulting in anaphylaxis.  
This study also allows for the examination of tuberculosis at 10 weeks post infection 
within non-human primates, which can provide valuable information regarding the acute stage of 
infection. Indeed, data from lung granuloma bacterial burden from the control animals in this 
study suggests that the immune system is still actively attempting to reduce lung granuloma 
bacterial numbers
44, 133
. PET/CT imaging employed in this study also seem to support this idea as 
lesion numbers and lymph node metabolic activity were comparable from animals from both 
Rituximab treated and saline control groups. Based on the observations in B cell depleted 
animals, it appears that B cells may not be playing a significant role in controlling infection at 
such an early stage. However, with the immune system still actively attempting to reduce 
bacterial numbers, it is difficult to directly attribute disease outcome with B cell depletion. B 
cells may very well be contributing towards disease control by more subtle means that is difficult 
to be measured at 10 weeks post infection. Longer future studies, with serial PET/CT scanning, 
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would help to resolve B cell contribution to tuberculosis control more clearly as it would permit 
lesion development to be tracked over the entire course of infection
133
.   
Within Rituximab treated animals, B cells, antigen specific antibody and total IgG were 
confirmed to be markedly diminished. The B cell clusters that are reminiscent of germinal 
centers (Chapter 5) within lung granulomas of animals treated with Rituximab were either 
reduced in size or absent entirely compared to control granulomas. However, T cell percentages 
as measured by flow cytometry were also slightly reduced. B cell clusters within the lung 
granulomas were previously characterized as being areas where antigen presentation occurs 
judging from the increased expression of MHC class II molecules and proliferation of B cells
214
. 
Absence of such clusters within the granulomas and reduced B cell follicles within the lymph 
nodes may thus reduce the efficacy of proliferation, activation, differentiation and trafficking of 
antigen specific T cells into the granuloma. Furthermore, a trend of increased IL2 production by 
T cells within Rituximab treated granulomas compared to saline control samples was noted but 
did not achieve statistical significance (p=0.05). This might reflect compensatory mechanisms 
within T cells to encourage further T cell expansion. Natural killer cells could also be present in 
higher numbers within Rituximab treated animals. Unfortunately, natural killer cell markers were 
not included in the panel of study, thus preventing any further possible explanations for the 
reduction in T cell percentages within B cell depleted animals.  
Findings at necropsy in terms of gross pathology, clinical disease manifestation and 
progression were unremarkable when comparing B cell depleted animals to the saline control 
counterparts. However, this data may indicate that at this acute stage of infection, the immune 
system is still in the process of controlling the spread of the bacilli. The most intriguing 
observation was the increase in median CFU on a per granuloma basis (by 0.5 log units) from B 
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cell depleted lung granulomas. Although the increase is modest, this does suggest that B cell 
depleted animal granulomas on average are not as capable as their control granuloma 
counterparts in controlling bacterial growth, at least at 10 weeks of infection.   
Cytokine production by T cells within the lung granulomas does not appear to be 
different within animals of both groups, at least for the production of IL17 or TNF. A trend of 
increased percentages of T cells making IL2 was observed within the Rituximab treated animals. 
Seeing as how both the T cell lymphocyte percentages and numbers were lower within 
Rituximab treated lung granulomas, the increase in IL2 production might be a way to 
compensate and induce T cell proliferation within sites of infection. Although the percentage of 
IFNγ secreting T cells were similar within B cell depleted animals and saline controls, the 
absolute numbers of IFNγ producing T cells, normalized to tissue weight, was lower within B 
cell depleted samples compared to controls. With lower numbers of IFNγ T cells, bacterial 
control within B cell depleted granulomas may be slightly impaired and may contribute towards 
the increased numbers of bacterial CFU recovered from Rituximab treated animals. The precise 
mechanism that leads to lower numbers of IFNγ producing T cells are unknown as there could be 
defects either in the generation or recruitment of IFNγ secreting T cells.     
The individual cytokine composition of the lung granulomas was not statistically 
different when comparing Rituximab treated samples against saline controls at least for IL10, 
IL17, TNF, and IFN-γ. Calprotectin, a marker of neutrophils, was not different as well within 
granulomas from either group, indicating that levels of inflammation between granulomas of 
both groups were comparable. The only notable difference in cytokine levels within the 
granuloma was IL6 where a trend of lower IL6 granuloma content was observed within 
Rituximab treated animals (p=0.08). This could be attributed to B cell depletion as B cells were 
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noted to secrete primarily IL6 in their cytokine secretion profile. Depleting B cells appears to 
result in a reduction in IL6 within infected tissues. These datasets are rather different from 
findings of B cell knockout mice infected with M. tuberculosis, where these mice had increased 
neutrophilic infiltrate and increased IL10 levels in the lungs
211, 234
. It is very likely that a 10 week 
low dose infection with M. tuberculosis for non-human primates is still in the acute phase unlike 
the mouse model of infection. Hence, a long term study of 6 months with M. tuberculosis 
infected NHPs undergoing B cell depletion might provide a much more conclusive answer. 
However, such extended depletion studies are likely not feasible due to adverse reactions to long 
term repeated administration of rituximab, as with other antibodies in non-human primates
105
.  
Although the cytokine levels themselves are not different within B cell depleted 
granulomas and saline control samples, the relationships between cytokines are skewed 
following B cell depletion. The most interesting observation was the change in the IL10 
relationship with IL17 within granulomas of Rituximab treated animals relative to controls (Fig. 
37). We demonstrated that B cells were capable of secreting both IL17 and IL10 (Fig. 13). 
Within control granulomas, B cells organize themselves into aggregates with germinal center 
features
214
 and thus cytokine secretion would presumably have roles in T helper cell 
differentiation and controlling inflammation. Rituximab treated animals lack B cells and thus, 
lack the cytokines contributed by B cells. The changes in cytokine correlations might hint at 
possible modulation of the granuloma cytokine environment. In murine tuberculosis models, an 
absence of B cells in infected mice results in increased neutrophil infiltration of the lungs and 
increased bacterial burden at the site of infection. It is possible that the increased IL17 and IL10 
content of control granulomas reflect the ability of B cells to recruit neutrophils and activate T 
cells within the ectopic germinal center clusters to limit bacterial growth while simultaneously 
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limiting bystander tissue damage via IL10 mediated activity. When B cells are absent, there are 
less T cells being activated, allowing for increased bacterial growth. This increase in bacterial 
burden results in the immune cells within the granuloma to start recruiting more neutrophils in an 
attempt to control bacterial numbers by secreting pro-inflammatory mediators. The increased 
inflammation in turn results in the increase of IL10 secretion, dampening down inflammatory 
activity and permitting bacterial growth again. This effectively sets up a vicious cycle of 
bacterial growth, increased neutrophilia and increased IL10 production as seen in the B cell 
knock-out mice tuberculosis model where more neutrophils are noted within the lungs along with 
elevated IL10 levels
211, 215, 234
. Within the B cell depleted animals, only increased bacterial 
burden is noted and a possible dysfunction in the relative cytokine levels of IL10 and IL17 
within the granuloma. However, this study only looked at 10 weeks of infection where the 
disease is still thought to be in the process of reaching a state of equilibrium with the immune 
system
44, 133
. A longer B cell depletion study would provide invaluable data in validating this 
proposed model.   
The other observation when assessing relationships between the various immune and 
bacterial parameters of the granuloma was the correlation of IL6 and bacterial burden (Fig. 34). 
Within saline control granulomas, IL6 levels positively correlated with granuloma bacterial 
burden, suggesting that more bacterial brings about more IL6 mediated activity. However, this 
relationship is absent in B cell depleted granulomas, suggesting that an inflammatory response 
element to bacterial burden is absent. A lack of pro-inflammatory signaling within these 
granulomas may explain the higher median bacterial burden among B cell depleted granulomas. 
IL6 mediated signaling in response to bacterial burden may thus be essential in encouraging pro-
inflammatory responses to limit bacterial growth within the granuloma. 
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This study shows that an absence of B cells did not significantly alter acute M. 
tuberculosis progression and outcome, at least up to 10 weeks. However, there are several 
observations that hint at possible differences namely the increased CFU within B cell depleted 
lung granulomas and the altered cytokine correlations. In a more chronic setting, these changes 
may be significant but for now the contribution of B cells to tuberculosis control is minimal in 
the acute setting.            
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7.0  MACROPHAGE BEHAVIOR IN B CELL DEPLETED MYCOBACTERIUM 
TUBERCULOSIS INFECTED CYNOMOLGUS MACAQUES  
7.1 ABSTRACT 
B cells and antibody are known to be capable of influencing macrophage activation phenotype 
and regulating inflammation in infection and autoimmunity. In murine M. tuberculosis infection 
models, FcγR mutants were noted to have different susceptibility or resistance to disease 
depending on various receptor knockouts and point towards the involvement of antibodies in 
regulating disease progression and inflammation. However, the mechanisms by which B cell and 
antibody regulating macrophage activation within the non-human primate model of tuberculosis 
have not been studied. This study aims to elucidate the relationship between B cell and 
macrophage activation states from non-human primate B cell depleted granulomas by examining 
the ratio of enzymes arginase 1 and inducible nitric oxide synthase (iNOS). These enzymes are 
differentially expressed within different macrophages depending on the mode of activation. 
Although both antibodies and B cells were shown to be depleted previously within Rituximab 
treated granulomas, the study did not find a difference in the levels of arginase 1 or iNOS 
expression within the lymphocytic cuff or the epithelioid macrophage layers of Rituximab 
treated or saline control granulomas. No difference was seen in the ratio of arginase 1 to iNOS 
within both regions of interest between the granulomas as well. This again reinforces the notion 
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that the contribution of the humoral immune system towards disease control at least at 10 weeks 
post infection is not significant.  
7.2 INTRODUCTION 
Macrophages represent a crucial cell population in the context of tuberculosis as they are the first 
cells that encounter the pathogen and are essential in eliminating the bacilli, if properly activated. 
However, should macrophage activation become uncontrollable, disease pathology worsens and 
allow for M. tuberculosis to disseminate. Thus, a balance of pro- and anti-inflammatory inputs to 
the macrophage is paramount in maintaining proper granuloma function in eliminating the 
bacilli.  
Cytokines such as IFNγ and TNF have proven to be essential in enhancing  macrophage 
killing of ingested M. tuberculosis bacilli and overcoming the phagolysosomal fusion blockage 
induced by the pathogen
84, 85, 103
. Excessive macrophage activation via inflammatory cues such as 
TNF and IFNγ is detrimental as it exacerbates tissue damage, as observed in the case of chronic 
disease such as tuberculosis
33, 71
.  
Inflammatory macrophages can be functionally characterized by assessing the amount of 
inducible nitric oxide synthase enzyme (iNOS) present. A high level of iNOS is required to 
generate reactive nitrogen and oxygen radical species from the degradation of arginine. These 
reactive radical species are one of the primary means by which inflammatory macrophages kill 
phagocytosed pathogens effectively
72
.  
Macrophages can also be activated into an alternative pathway that promotes tissue 
remodeling via the production of IL4
249
, and dampening of immune activation via IL10 
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production
41, 76, 77
. In murine models of tuberculosis, IL10 appears to induce macrophage 
alternative activation rather than IL4
112, 250
. Such alternative activation is thought to be important 
in reducing inflammatory damage and promote healing especially in the context of large helmith 
infections
249
. Macrophages that are activated via this route have been shown to upregulate the 
levels of arginase, an enzyme that degrades the amino acid arginine into ornithine. Arginase is 
thought to compete with iNOS for arginine as a substrate, thus decreasing the available pool of 
arginine for the production of reactive radical species
246, 251
. Macrophage behavior can thus be 
inferred by determining the relative levels of iNOS and arginase enzymes as arginine metabolism 
is tied in to microbicidal activity of the macrophage.  
The goal of this study is to determine whether the absence of B cells and more 
importantly antibody affects the pattern of macrophage activation within the granuloma. This 
was done by examining the relative ratios of arginase to iNOS within the lung granulomas from 
B cell depleted and saline control animals. Inappropriate macrophage activation in the context of 
an infection is detrimental as immune cells are not able to effectively contain and eliminate the 
pathogens
78, 79, 241
. By understanding the factors that dictate macrophage activation, future 
treatment modalities or vaccines can be developed to direct macrophage activation within the 
appropriate context to maximize bacterial killing but minimizing tissue pathology. 
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7.3 MATERIALS AND METHODS 
7.3.1 Tissue processing 
Granuloma tissues identified at necropsy were flash frozen in liquid nitrogen prior to storage at 
−80°C. Samples were then homogenized by disrupting the tissue on 40μm cell strainers (BD 
Falcon, Franklin Lake, NJ) in PBS containing 0.1% Triton X-100 and protease inhibitor mixture 
(Thermo Fisher Scientific) without EDTA under BSL3 conditions. The homogenate was then 
filtered through a 0.22μm syringe filter. 
 
7.3.2 iNOS enzyme assay 
The iNOS enzyme assay done as described previously
246
. In brief, iNOS activity was determined 
using a cell lysate based assay that measured nitrite (NO2
-
) via the Griess reaction. Samples were 
prepared in the presence or absence of N6-(1-iminoethyl)-l- lysine (L-NIL; Cayman Chemical), a 
selective iNOS inhibitor to isolate the contribution of iNOS from other NOS enzymes. 
 
7.3.3 Arginase enzyme assay 
The arginase enzyme assay was performed as described
251
. In brief, arginase activity was 
assessed by measuring the amount of 
14
CO2 generated from the conversion of L-[guanidino-
14
C] 
arginine as a substrate by arginase within the tissue homogenates into [
14
C] urea. The 
14
CO2 is 
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generated by adding Jack Bean urease (Sigma, St. Louis, MO) to facilitate the conversion of 
[
14
C] urea to 
14
CO2. 
14
CO2 generated is trapped by NaOH soaked grade 3 Whatman paper discs 
(GE Healthcare, UK).   
 
7.3.4 Immunohistochemistry 
Paraffin embedded slides of relevant tissue sections were stained as described
246
. Briefly, 
sections were stained with mouse anti-human arginase 1 (BD Transduction, Lexington, KY), 
mouse anti-human CD68 and rabbit anti-human iNOS (Neomarkers, Fremont, CA) antibodies 
after antigen retrieval processing. Images were taken at 20x magnification and serial images 
were used to generate a composite of the tissue section. 
 
7.3.5 Data analysis 
Data were analyzed using Prism 6 (Graphpad Software, San Diego, CA). All data are shown as 
medians to account for the variability of the data. Statistical comparisons were performed using 
Mann-Whitney test with p<0.05 considered statistically significant. Paired samples were 
analyzed using the Wilcoxon matched-pairs signed rank test with the same threshold, p<0.05 as 
being statistically significant.  
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7.4 RESULTS    
7.4.1 Biochemical analysis of lung granulomas 
 
Figure 38. Biochemical quantification of iNOS enzymes within granuloma samples. No statistically significant 
difference in iNOS enzyme quantification was found between granuloma samples of B cell depleted and saline 
control groups. Each dot represents 1 sample.  
 
Tissue homogenate prepared from freshly frozen lung granulomas obtained at necropsy were 
used in to assess the activity of iNOS, as a surrogate measurement of classical activation of 
macrophages, within the total protein content of tissue homogenates obtained at necropsy. The 
amount of iNOS enzyme activity is quantified by measuring the amount of nitrite produced in 
the presence or absence of a specific iNOS inhibitor, L-NIL. The iNOS inhibitor is needed to 
differentiate the activity of iNOS from other related nitric oxide synthase enzymes such as neural 
nitric oxide synthase (nNOS) and epithelial nitric oxide synthase (eNOS). Data obtained from a 
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total of 7 granulomas revealed no difference in terms of percent iNOS from total protein between 
B cell depleted and saline control granulomas (Fig. 38.).  
 
Figure 39. Biochemical quantification of Arginase 1 enzyme within granuloma samples. No statistically significant 
difference in Arginase 1 enzyme amount was found between granuloma samples of B cell depleted and saline 
control groups. Each dot represents 1 sample. 
 
Arginase 1 activity was performed as a surrogate quantification of alternatively activated 
macrophages present within the granuloma. Tissue homogenates obtained from frozen lung 
sections were used to assess for arginase 1 activity by measuring the amount of 
14
CO2 released 
used in the assay. The arginase 1 activity is calculated by normalizing the activity in the sample 
to the overall protein content. Analysis of granuloma samples obtained from Rituximab treated 
or saline control animals revealed no difference in arginase 1 activity between granulomas from 
both groups (Fig. 39.). 
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7.4.2 Assessment of enzyme expression patterns for Arg1 and iNOS within the 
granuloma 
Paraffin embedded sections of lung granulomas from B cell depleted and control animals were 
stained for CD68 to identify macrophages, and enzymes arginase 1 and iNOS (Fig. 40A). CD68 
staining was used to locate the epithelioid macrophage layer and approximate the lymphocytic 
cuff
246
. Pixel intensity analysis was performed to quantify the amount of arginase 1 and iNOS 
staining present within the different regions of the granuloma (Fig. 40B)
246
. Levels of arginase 1 
and iNOS within either the epithelioid macrophages or lymphocytic cuff were not statistically 
different when comparing B cell depleted granulomas with saline control samples. No 
differences were seen when comparing the change in ratio of arginase 1 to iNOS between the 
lymphocytic cuff and the epithelioid macrophage layer of B cell depleted and saline control 
granulomas (Fig. 40C).  
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Figure 40. Histological staining and analysis of NHP granulomas for iNOS and arginase 1 enzyme. A) Staining of 
lung granulomas from Rituximab treated and saline control granulomas for presence of iNOS (green) and arginase 
1(red). CD68 (blue) was used to identify the epithelioid macrophage layer (yellow) and lymphocytic cuff (pink). B) 
Quantification of the amount of iNOS and arginase 1 present using pixel intensity of the regions of interest within 
the granuloma and comparing the findings of Rituximab treated and saline control samples. C) Comparison of the 
ratio of arginase 1 to iNOS within the epithelioid macrophage and lymphocytic cuff regions of granulomas from 
Rituximab treated animals and saline controls.  
7.5 DISCUSSION 
This study was carried out to determine whether there is a relationship between macrophage 
activation, as measured by the amount of enzymes arginase 1 and iNOS, and B cells, more 
specifically antibodies. This was done by comparing granulomas obtained from B cell depleted 
and saline control animals. Antibodies are thought to be capable of influencing macrophage 
activation based on the size of the immune complex
77, 206, 222
. The goal of this study was to 
determine if macrophage behavior within different regions of the granuloma would change in the 
absence of B cells or antibodies that generate immune complexes with M. tuberculosis antigens.  
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The B cell depleted animals were infected for a period of 10 weeks with M. tuberculosis 
and no differences in the outcome of infection were seen between B cell depleted and saline 
control animals at necropsy. Data from the biochemical analysis of the enzymes arginase 1 and 
iNOS seem to corroborate with previous observations that disease progression seems to be 
largely unchanged within the granuloma at 10 weeks post infection. Histological staining for 
arginase 1 and iNOS also show that macrophage behavior within the granulomas of B cell 
depleted animals to be very similar to macrophages found within the granulomas of saline 
control animals suggesting that macrophages are similarly activated.  
It is known that antibodies are capable of activating macrophages into different activation 
states
205, 206
 or manipulate the signaling threshold for macrophages via interactions with the Fc 
receptors
159, 198, 201
.  However, the contribution by antibodies towards regulating macrophage 
activation in tuberculosis is unknown. Although data from the previous chapter showed that M. 
tuberculosis specific antibodies were markedly reduced within B cell depleted granulomas, 
macrophage behavior and activation, at least as measured by expression of iNOS or arginase, 
markers for classically and alternatively activated macrophages, did not seem to differ compared 
to control granulomas. Due to the short period of the study, it is possible that the effects of 
antibody on macrophage activation states were not noticeable given the chronic nature of 
tuberculosis. A longer observation period up to around 5 months may provide more clarity on the 
outcome of infection with B cell depletion. Future vaccination formulations may benefit from 
elucidating the mechanisms of macrophage activation by antibody.    
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8.0  IMPLICATIONS OF THESIS FINDINGS 
Immunity towards M. tuberculosis requires a complex set of interactions between the various 
players of the immune system to orchestrate bacterial containment within the granuloma. A great 
deal of effort focused on deciphering how cellular immunity contributes toward tuberculosis 
control has yielded a greater understanding on the important variables involved in granuloma 
formation and function
36, 38, 41, 69, 94, 135, 136, 219
 and future vaccine development to augment cellular 
immunity against M. tuberculosis
127, 130, 134
. However, less is known regarding the humoral 
response in tuberculosis. Antibodies may not be effective in neutralizing intracellular 
pathogens
50, 209, 210
 but may play a role in regulating immune cell activation
158, 202, 206, 216
. 
Furthermore, B cells are recognized as cytokine sources during infection and autoimmunity
164, 238
 
and thus present a tantalizing target in modulating cellular activation within the granuloma.    
8.1 B CELLS FORM ECTOPIC GERMINAL CENTERS WITHIN THE 
GRANULOMA 
Several studies with human granulomas have drawn parallels of the tuberculous granuloma with 
ectopic lymphoid tissue
212, 213, 231, 232
 due to the clustered appearance of B cells. Within infected 
cynomolgus macaques, B cells were found to be organized in distinct clusters at the lymphocytic 
cuffs of the granuloma, analogous to the black spots on a white soccer ball (Fig. 41.). These 
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clusters were also observed to be reminiscent of ectopic lymphoid structures due to the 
expression of germinal center and cell proliferation markers
214
. These findings suggest that B 
cells are providing T cell help at the site of infection within the ectopic lymphoid tissue clusters. 
 
Figure 41. Cartoon depiction of the soccer ball hypothesis. This figure illustrates the location of B cell clusters (red) 
within the lymphocytic cuff and on the surface of a granuloma. 
8.2 IMPLICATIONS OF B CELL CYTOKINE PRODUCTION 
The cytokine secretion profile of lymphocytes suggests that approximately 20 percent of B cells 
within the granuloma are mainly producing IL6, IL17 or IL10 in various combinations with a 
separate, smaller population secreting TNF or IFNγ (Fig. 13. and 14.).  
IL6 production by B cells has been noted to a main factor in driving pathology in 
autoimmunity possibly by driving T cell differentiation into Th17 cells
165, 226
. Most recently, IL6 
expression levels have been identified to be elevated within lungs of vaccinated and M. 
tuberculosis infected cynomolgus macaques
252
. However, in the context of infection, IL6 
production by B cells may be essential in providing an impetus for T cell activation. 
Furthermore, IL6 together with transforming growth factor β (TGFβ) has been noted to restrain 
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excessive Th17 mediated pathology
253, 254
. The studies detailed here have established IL6 to be an 
essential cytokine produced by B cells. Furthermore, IL6 levels within the granuloma appear to 
be different from control granulomas in the absence of B cells. It is thus possible that B cells are 
capable of modulating excessive inflammation within the granuloma while encouraging T cell 
activation to contain the bacilli. However, IL6 knockout mice with M. tuberculosis infection only 
showed a slight delay in the induction of IFNγ but no impairment in bacterial control255. 
Nonetheless, inflammation was not rigorously assessed in these mice studies and the study 
period was not sufficiently long to look at the effects of IL6 ablation in chronic infection. It 
would thus be possible to further assess the role of IL6 in tuberculosis control within the murine 
model due to the genetic tractability of the animal. Understanding the specific contribution of B 
cell IL6 may shed further light on the role of IL6 in the development of T cell responses to 
tuberculosis and neutrophil recruitment.    
IL17 has been known to provide help to T cells in recruiting IFNγ within the 
granuloma
256-258
. B cells may be providing an alternative source of IL17 to assist in the 
recruitment of IFNγ production by T cells, particularly within the ectopic lymphoid tissue 
clusters. An absence of B cells may result in less efficient T cell recruitment into the granuloma 
particularly T cells secreting IFNγ, which was noted within the B cell depleted granulomas 
where there were less IFNγ secreting T cells. IL10 produced by B cells may provide anti-
inflammatory cues to dampen down excessive T cell and macrophage activation. However, the 
interplay between these cytokines in precisely modulating immune activation in response to 
infection is unknown. The intriguing point to note is that B cells, being organized into 
lymphocytic clusters, will come into close contact with T cells within the granuloma. Although 
no significant differences were noted for T cell and macrophage responses during the acute phase 
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of tuberculosis (10 weeks) in the B cell depletion study, the long term cytokine contribution from 
B cells toward tuberculosis control remains uncharacterized.  
It is thus entirely within the realm of possibility that cytokines being produced by B cells 
are helping to maintain pro- and anti-inflammatory responses within the granuloma in an attempt 
to limit bacterial growth and bystander tissue damage. Furthermore, B cells may be coordinating 
such pro- and anti-inflammatory responses between T cells via possible IL6 mediated Th17 
responses, neutrophil recruitment and bacterial control (Fig. 42.). An absence of B cells means 
that such a concerted response is not formed, leading to a runaway cycle of uncontrolled 
bacterial growth and excessive inflammation as seen in the mouse model
211
. 
 
Figure 42. Cartoon depicting the possible roles of cytokines IL6, IL17 and IL10 produced by B cells within the 
granuloma. B cells produce pro-inflammatory cytokines IL6 and IL17 which together with Th17 T cells recruits 
neutrophils to assist in bacterial clearance. B cells also produce IL10 to provide a check on excessive inflammatory 
infiltrate. The germinal center configuration of B cells within the granuloma allows for close contact with T cell that 
may limit the scope of immune activation by cytokines.  
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8.3 THE EFFECTS OF B CELL DEPLETION IN THE NON-HUMAN PRIMATE 
MODEL OF INFECTION 
The primary limitation in the B cell depletion study was that it was 10 weeks long due to issues 
with drug interactions within the treated animals. The earlier cohort of Rituximab treated animals 
developed anaphylactic reactions towards the drug, such that the B cell depleted state could not 
be safely maintained beyond 10 weeks, necessitating the early termination at 10 weeks post 
infection.  
The general conclusion drawn from the B cell depletion study was that disease 
progression at 10 weeks remains unchanged between Rituximab treated and saline control 
groups. Findings at necropsy did not reveal any significant differences in animals from B cell 
depleted or control groups, both presenting with comparable amounts of disease and 
dissemination. Tissue pathology did not appear to be different as granulomas from both groups 
were highly similar in appearance upon standard histological staining (hemotoxylin and eosin). 
The only notable difference was that the lymphocytic cuff was less prominent within Rituximab 
treated animals and was attributed to the ongoing B cell depletion.  
Immune parameters within the granuloma were also comparable between Rituximab 
treated animals and saline controls. T cell cytokine production was not found to be significantly 
different between both group while total cytokine quantification and macrophage function was 
noted to be similar in general. However, the correlation between the tested cytokines IL10, IL17, 
IL6 and bacterial burden were noted to be different between the Rituximab treated and saline 
control granulomas. This difference means that the cytokines present within each individual 
granuloma from saline control and B cell depleted animals are different and highlights possible 
points of control by B cells. It is possible the B cells are providing the immunological support via 
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cytokine signaling within the germinal center to T cells to ensure efficient control of bacterial 
burden within the granuloma thus leading to proper long term bacterial control that reduces 
tissue pathology. An absence of B cells abolishes the coordination of various cell functions that 
would be detrimental in the long term when bacterial numbers are not properly controlled. 
Indeed, within the 10 weeks of infection, a subset of granulomas within the B cell depleted 
animals was noted to have higher bacterial burden compared to control granulomas (Fig. 43.). 
    
Figure 43. Cartoon depicting the possible effect of B cell depletion within the granuloma. The absence of B cells 
results in a lack of efficient bacterial clearance. The higher bacterial burden results in more inflammatory cues such 
as increased neutrophil recruitment. The influx of inflammatory cells requires a lot more anti-inflammatory 
signaling to resolve. The inadequate coordination of pro- and anti-inflammatory activity within a B cell depleted 
granuloma leads to a vicious cycle of increasing neutrophil infiltrate and elevated IL10 production to reduce 
inflammation. 
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B cell depleted animals also did have a statistically higher median bacterial burden per 
granuloma compared to control animals. This may indicate that B cell depleted granulomas are 
less able to control M. tuberculosis compared to the saline control group granulomas. However, 
the difference in bacterial burden is not attributed to T cell cytokine secretion and macrophage 
activation as both parameters were not observed to be significantly different, at least according to 
readouts used in the above studies (Chapter 6 and 7). The contribution of humoral immunity may 
be very subtle and involve pathways that were not included in the above studies, such as FcγR 
receptor expression and function and possible contribution of cytokines. 
8.4 FUTURE AVENUES OF STUDY     
Bacterial enumeration within infected tissues were done via 7H11 agar plate culture which only 
takes into account of live bacteria. An alternative method to assess B cell contribution towards 
bacterial control may be to use chromosomal equivalence unit analyses to determine the total 
bacterial population originally present within the granuloma, both live and killed. This method 
may reveal the efficacy of the granuloma in controlling the disease by measuring bacterial killing 
efficiency.  
Longer B cell depletion studies have been proposed to adequately address the role of B 
cells in controlling tuberculosis within primates. However, another aspect that could be address 
is delayed B cell responses upon infection. This could be done by depleting the animals of B 
cells prior to infection and then allowing the B cell population to recover at a predetermined 
period after infection. This can provide valuable data in how the B cell response is shaped and 
the implications of a late B cell response on disease control.   
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One possible aspect of humoral immunity was not pursued due to a lack of specialized 
reagents for non-human primate use was the characterization of the Fc receptors within the 
granuloma. Fc receptors, particularly FcγR receptor members were shown to influence disease 
outcome in M. tuberculosis infected mice
216. Indeed, FcγR are major mediators of macrophage 
activation
205, 206
 and are known to regulate the activity of multiple cell types
52, 201, 202
. With 
regards to macrophage activation within the granuloma, FcγR receptors are suspected to 
influence macrophage activation thresholds based on the size of the immune complexes present. 
Immune complex sizes are, in turn, influenced by the levels of antibody and antigen present (Fig. 
44.) within the granuloma. Thus, the interaction between antibody immune complexes and FcγR 
potentially contribute towards generating the broad spectrum of granuloma microenvironment 
observed. Unfortunately, the reagents to reliably distinguish activating and inhibitory FcγR in 
macaques do not exist, and thus these studies cannot be reliably performed in this model at this 
time. 
Another approach in determining the contribution of antibodies and FcγR receptors is to 
administer intravenous immunoglobulin (IVIg) purified from pooled cynomolgus macaque 
serum. Human IVIg has been used as an immunosuppressant to treat autoimmune conditions 
such as lupus and rheumatoid arthritis
247, 248
. IVIg is thought to modulate immune activity by 
engaging inhibitory FcγR receptors along with recruitment of inhibitory glycans on immune cells 
particularly macrophages, B cells and neutrophils
248, 259, 260
. By supplementing IVIg into B cell 
depleted animals, it may be possible to resolve the contribution of B cell cytokine production and 
antigen presentation from antibody mediated contributions toward control of tuberculosis. 
In the B cell depletion study, the level of antigen specific antibody was confirmed to be 
reduced within the Rituximab treated animals. Despite the difference, no further effects were 
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seen in terms of granuloma pathology, disease progression, cytokine secretion by T cells or 
macrophage behavior between B cell depleted and saline control animals. Again, the results 
show that humoral responses do not seem to be crucial in modulating immunity towards 
tuberculosis at 10 weeks post infection. However, the longer term effects are still unknown and 
future studies should take into account longer B cell depletion periods, if possible.       
 
 
Figure 44. Cartoon details the proposed model describing the mechanism of macrophage activation being 
modulated by antibody antigen immune complexes via FcγR recruitment.  
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8.5 OVERALL CONCLUSION 
It would appear that the contribution of humoral immunity towards the control of M. 
tuberculosis infection within the cynomolgus macaque model of tuberculosis is minimal at 10 
weeks post infection. Disease progression is essential unremarkably different within B cell 
depleted animals compared to saline controls, although bacterial containment is slightly impaired 
within B cell depleted granulomas. Pathological observations and immune parameters appear to 
be similar although differences were noted in terms of cytokine composition on the individual 
granuloma level. Long term contributions by the humoral component of immunity towards 
tuberculosis control remains to be determined but is suspected to be more significant. By 
understanding how the humoral components of immunity interact with other immune players 
within the granuloma, it is possible to enhance future vaccine and novel therapy developments to 
maximize immune mediated bacterial clearance while minimizing tissue damage.  
The studies detailed here indicate that B cells and antibody are not essential for control in 
the early phase of natural M. tuberculosis infection. Nonetheless, the roles of B cells and 
antibody responses in chronic infection and vaccination models, in particular, are poorly 
understood. Furthermore, antibody based vaccination against M. tuberculosis is just beginning to 
be explored
261
 but has yet to be adequately developed in any animal model system. The outcome 
of recent human vaccination trials for M. tuberculosis has shown that simply inducing higher T 
cell responses is insufficient for adequate protection against infection
262-264
. Augmenting the 
natural ability of the host to control infection by antibody production may be a viable alternative 
since T cell based vaccination strategies have thus far been inadequate in eliciting full vaccine 
protection against M. tuberculosis in any animal model system.  
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APPENDIX A: SUPPLEMENTARY FIGURES 
  
Table 2. Non-parametric Spearman’s ρ correlation of granuloma parameters used in linear correlation analysis of 
saline control animal samples. 
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Table 3. Non-parametric Spearman’s ρ correlation of granuloma parameters used in linear correlation analysis of 
Rituximab treated animal samples. 
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